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Colorectal cancer is the third most commonly diagnosed cancer worldwide and the fourth 
leading cause of cancer-related death. The etiology of colorectal cancer is predominately 
attributed to modifiable lifestyle factors that promote chronic inflammation, and only 20% of 
colorectal cases are credited to hereditary syndromes. Specifically, recent nutritional studies have 
suggested that diet modification is a promising lifestyle intervention for reducing systemic 
inflammation and promoting colorectal cancer prevention and remission. In particular, rice and 
navy beans have been identified as two foods with anti-inflammatory and anti-neoplastic 
properties that warrant evaluation for chemoprevention through dietary supplementation in 
humans. In this study, plasma cytokines (IL-2, IL-4, IL-6, IL-8, IL-10, TNF, and VEGF) and 
leukocyte telomere length were measured at baseline, two weeks, and four weeks in individuals 
with and without a history of colorectal cancer who consumed a diet supplemented with rice 
bran, navy beans, or a placebo-control for 28 days. Serum lipid profile and nutrient intake were 
also measured. At baseline, the three diet intervention groups had no significant differences in 
cytokine concentration, telomere length, or lipid profile. At the end of the study, individuals with 
a history of colorectal cancer who consumed the navy bean supplemented diet had significantly 
higher plasma TNF and VEGF concentrations than individuals consuming the control diet. 




telomere length between groups existed. Additionally, compared to males, females with a history 
of colorectal cancer had significantly longer telomeres at baseline but not at four weeks. Females 
with a history of colorectal cancer also had significantly lower IL-4, IL-6, and IL-10 at baseline, 
but no significant difference was found at four weeks. Linear correlation analysis on repeated 
measures that adjusted for sex, age, and total energy intake showed significant correlations 
between several study variables. Telomere length was inversely correlated with age, serum 
triglyceride level, carbohydrate intake, and saturated fat intake. IL-2 and IL-4 concentrations 
were inversely correlated with α-Tocopherol intake. IL-8 was inversely correlated with vitamin 
B3 intake. VEGF was positively correlated with vitamin B9 intake. Total serum cholesterol was 
positively correlated with saturated fat intake and inversely correlated with β-Carotene intake. 
Serum LDL was inversely correlated with β-Carotene intake, and serum HDL was positively 
correlated with intake of saturated fat and linolenic acid. Triglyceride level was inversely 
correlated with intake of β-Carotene and fiber and was positively correlated with selenium 
intake. Finally, comparison of two experimental methods for telomere length measurement 
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Colorectal cancer is the third most commonly diagnosed cancer worldwide and the fourth 
leading cause of cancer-related death.[1] The distribution of colorectal cancer varies by location, 
with higher prevalence and incidence in more developed nations, and within the United States, 
the lifetime risk of developing colorectal cancer is 1 in 20.[1-3] Numerous studies have 
associated the risk of colorectal cancer development with several modifiable lifestyle factors, and 
by some estimates, approximately half of all colorectal cancer in the United States may be 
preventable through maintaining an appropriate diet, physical activity level, and body weight.[1, 
4] Fortunately, due to increased screening and improved methods of treatment, the mortality rate 
of colorectal cancer has progressively declined over the last several decades, and today, the 5-
year relative survival rate for early stage colorectal cancers is approximately 90%.[2] As a result, 
there are over 1 million people in the United States with a past medical history of colorectal 
cancer, and recent observational studies of this population have suggested the modification of 
high-risk lifestyle factors as a promising intervention for the prevention of colorectal cancer 
recurrence.[5-7]  
 The etiology of colorectal cancer is predominately attributed to modifiable lifestyle 
factors with only 20% of cases credited to hereditary syndromes, such as familial adenomatous 
polyposis, and the most significant lifestyle factors related to colorectal cancer occurrence 
include physical inactivity, obesity, smoking behavior, alcohol use, and poor dietary habits.[8-
15] These factors all have a shared tendency to induce chronic inflammation, which is strongly 
implicated in the development and progression of colorectal cancer and multiple other 




The significance of inflammation in the development and promotion of colorectal cancer 
is strongly supported by data demonstrating the protective effect of long-term aspirin and non-
steroidal anti-inflammatory drug (NSAID) use.[18-21] However, the chronic use of these drugs 
is often problematic; they are known to cause adverse effects, such as gastrointestinal ulcers or 
bleeding, and their use is not appropriate for individuals with contraindicating conditions, such 
as liver disease or coagulopathies.[22, 23] Consequently, non-pharmaceutical alternatives for 
reducing inflammation, such as through diet and physical activity interventions, have arisen as 
promising approaches for the prevention of colorectal cancer incidence and recurrence.[7, 24-28] 
In this study, the potential for a 28-day dietary intervention program to modulate blood 
biomarkers of inflammation and aging in a population of healthy individuals with and without a 
history of colorectal cancer was investigated. Specifically, the effect of a rice bran or navy bean 
supplemented diet on the concentration of seven distinct circulating plasma cytokines and on 
leukocyte telomere length was explored. The primary hypothesis of this investigation was that 
individuals who consumed a rice bran or navy bean supplemented diet for 28 days would have 
lower levels of inflammatory plasma cytokines and display slower rates of leukocyte telomere 
degradation compared to individuals who consumed a control diet. As a secondary component, 
potential correlations between plasma cytokine concentrations, leukocyte telomere length, serum 
lipid profile, and nutrient intake were examined with the supposition that poor dietary habits 
would be associated with dyslipidemia, increased inflammatory cytokine levels, and relatively 
shorter leukocyte telomeres. Lastly, a final goal of this study was to compare and assess the 
degree of correlation between two distinct experimental methods for telomere length estimation: 









1.1 Colorectal cancer, inflammation, and cytokines 
Chronic inflammation results from the dysfunction of acute inflammatory processes. In 
healthy individuals, acute inflammatory responses to cellular injury caused by infectious, 
chemical, or mechanical stimuli occur rapidly and are mediated by immune cells, cytokines, cell-
adhesion molecules, complement peptides, and other specialized molecules through the induction 
of vasodilation, vascular permeability, chemotaxis, and phagocytosis.[29] In the setting of 
persistent, systemic inflammatory stimulation, such as with regular cigarette smoking or red meat 
consumption, acute inflammatory processes designed to protect against cellular insult progress 
into chronic inflammation and self-harm.[30-33]  
The association between inflammation and cancer development is well established, and 
prolonged immune activation has been shown to increase the likelihood of carcinogenesis 
through multiple mechanisms including the accumulation of chromosomal mutations via reactive 
oxygen species (ROS), the promotion of angiogenesis by proliferative growth factors, and the 
inhibition of apoptosis through oncogenic signaling molecules.[9, 16, 34-40]  
Inflammatory processes are driven by cytokines, a large class of low molecular weight 
glycoproteins produced by both immune and non-immune cells in order to regulate the immune 
system.[17, 29] Cytokines play a vital role in mediating immunity, inflammation, and 
hematopoiesis by activating genes for growth, differentiation, and cell activity, and there is 
substantial evidence to show their utilization by tumors for progression and survival.[41, 42] 
Furthermore, individual cytokines are often pleiotropic, and thus able to exert multiple effects 




redundancies, synergisms, and antagonisms, which enable coordinated regulation of amplitude 
and duration of immune responses.[43] Finally, the synthesis and secretion of cytokines is often 
brief and self-limiting, and due to their potency, small changes in circulating cytokine 
concentrations can produce dramatic effects.[43]  
Chronic systemic inflammation secondary to environmental risk factors is 
overwhelmingly implicated in the development and progression of colorectal cancer.[9, 39, 40] 
Interleukin-6 (IL-6) and tumor necrosis factor (TNF) are two particularly inflammatory 
cytokines that play key roles in the initiation and progression of inflammation-associated 
cancers.[17, 44] Both cytokines are potent inducers of reactive oxygen species, which have been 
shown to increase genomic instability and promote carcinogenesis.[39, 45] Additionally, IL-6 
and TNF regulate the proliferation, survival, invasion, and metastasis of cancer cells through 
induction of pro-tumorigenic transcription factors such as Signal Transducer and Activator of 
Transcription 3 (STAT3) and Nuclear Factor-κΒ (NF-κΒ), respectively.[17, 44, 46-50] 
Accordingly, higher systemic concentrations of IL-6 and TNF are associated with both colorectal 
cancer occurrence and severity.[51-58] 
Other cytokines with significant effects on chronic inflammation and colorectal 
carcinogenesis include interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), 
interleukin-2 (IL-2), interleukin-10 (IL-10), and interleukin-4 (IL-4).   
IL-8 is a potent chemotactic factor for neutrophils and plays a significant role in 
angiogenesis.[59, 60] IL-8 directly regulates angiogenesis through promoting endothelial cell 
proliferation and inhibiting apoptosis via surface receptor binding.[61] This process also 
enhances the activity of proteinases involved in the breakdown of the extracellular matrix.[61] 




growth factor.[62-64] IL-8 is primarily produced and secreted by macrophages through NF-κΒ 
pathways activated by pro-inflammatory cytokines such as TNF, and within tumor 
microenvironments, macrophage overexpression of IL-8 contributes to invasion and 
metastasis.[65-67] Consequently, high concentrations of IL-8 are strongly associated with 
colorectal carcinoma occurrence, development, prognosis, and recurrence.[68-73]  
VEGF is a platelet-derived growth factor capable of highly specific mitogenic activity on 
endothelial cells.[74] VEGF expression is directly stimulated by STAT3 activity, and similar to 
IL-8, binding between VEGF and receptors on the vascular endothelium promotes endothelial 
cell proliferation and expression of molecules required for reorganization of the extracellular 
matrix.[74-76] These processes initiate angiogenesis, and thus are vital for normal growth and 
wound healing. However, they also perform an essential function in solid tumor development 
and progression, and higher concentrations of serum VEGF are associated with colorectal cancer 
occurrence, severity, and recurrence.[71, 77-81] 
IL-2 occupies a critical role in regulating inflammatory immune responses, and it has 
both dual and complementary functions through its ability to both provoke and inhibit 
inflammatory immune processes.[82] IL-2 displays pro-inflammatory properties through its 
ability to stimulate T cell proliferation and survival, promote CD8+ T cell and natural killer (NK) 
cell cytolytic activity, and control naïve CD4+ T cell differentiation into T helper 1 (Th1) 
cells.[83-88] Additionally, IL-2 possesses anti-inflammatory functions by modulating systemic 
inflammation through maintaining peripheral levels of Treg cells, a subset of T cells with 
immunosuppressive properties, and inhibiting differentiation of T helper 17 cells (Th17), a subset 
of T cells that secrete pro-inflammatory cytokines such as IL-6.[89-92] Both Treg and Th17 cells 




inflammatory diseases such as inflammatory bowel disease.[45, 92, 93] However, given the 
contrasting regulatory functions of IL-2, the implications of high serum IL-2 are not well 
understood. While at least one study has found an association between high plasma IL-2 and 
reduced colorectal cancer recurrence, multiple other studies have failed to reproduce similar 
findings, and a robust association between IL-2 and colorectal cancer risk has not been 
established.[83, 94-96]  
IL-10 is an anti-inflammatory cytokine that exerts significant immunosuppressive effects 
through its ability to suppress the secretion of inflammatory cytokines by Th1 cells, Th17 cells, 
and macrophages and to prevent antigen presentation by dendritic cells, macrophages, and B-
cells.[97-100] IL-10 is secreted by nearly all leukocytes, as well as tumor cells, and it limits 
immune responses and promotes homeostasis by activating STAT3 signaling pathways that 
selectively prevent cytokine expression.[101-103] Depending on the context, IL-10 has both pro-
tumorigenic and anti-tumorigenic abilities. Through curtailing chronic inflammatory processes, 
IL-10 exhibits a capacity for preventing tumor initiation and progression in healthy tissues, and 
several in vitro and animal models support this concept.[104-108] However, in the presence of 
established tumors, IL-10 can encourage proliferation and metastasis by suppressing anti-cancer 
immune responses.[104, 109, 110] In this regard, several observational studies have found a 
positive correlation between elevated serum IL-10 concentration and colorectal cancer severity 
and prognosis.[96, 111-113]  
IL-4 is generally labeled as an anti-inflammatory cytokine given its capacity to inhibit 
macrophages and suppress secretion of pro-inflammatory cytokines such as TNF via activation 
of Signal Transducer and Activator of Transcription 6 (STAT6) pathways.[114-116] Early in 




was initially investigated as a possible stimulatory target for cancer immunotherapy.[117, 118] 
However, later studies implicated IL-4 as a tumor promoter through demonstrating its ability to 
inhibit apoptosis and stimulate angiogenesis in mature cancer cells.[119-121] Recently, IL-4 has 
been observed to be secreted by and prevent the death of colorectal cancer stem-like cells, a 
small population of self-regenerating and treatment-resistant cells that support the initiation and 
progression of colorectal tumors.[122-124] Accordingly, elevated serum IL-4 concentration in 
colorectal cancer patients has been associated with poor disease prognosis.[55] However, the 
association of serum IL-4 concentration with colorectal cancer initiation or recurrence has not 
been strongly established, and several studies have not observed a significant correlation 
between serum IL-4 and colorectal cancer risk.[125-127] 
Overall, dual and contradicting effects that are dependent on the duration, magnitude, and 
setting of the immune response characterize inflammation in relation to colorectal cancer. A 
properly regulated inflammatory response protects against malignancy and is critical for the 
maintenance of host tissue integrity. However, when this process is prolonged or impaired, such 
as during chronic, low-grade insult by environmental stimuli, the likelihood of carcinogenesis is 
amplified. Additionally, an immune response can have drastically different consequences 
depending on its local surroundings. This is evidenced within the tumor microenvironment, 
where an anti-inflammatory or wound healing immune mechanism may be hijacked to promote 
tumor proliferation and invasion. Thus, the interpretation of immunological data is not a 
straightforward endeavor, and at this time, definitive conclusions regarding the exact effect of a 
specific cytokine level in an individual are impractical and unrealistic. Nevertheless, the 




greater comprehension and understanding of inflammation’s role in disease and has led to the 
development of numerous immunotherapies.[128, 129]  
 
1.2  Colorectal cancer and telomere length 
Telomeres cap the ends of human chromosomes and play critical roles in maintaining 
genome stability.[130, 131] The specialized nucleoprotein structure of telomeres prevents loss of 
genetic material after each cycle of replication and protects against recombination with other 
chromosomes.[132] Composed of tandem nucleotide repeats (5’-TTAGGG-3’) and an array of 
associated proteins, human telomeres progressively shorten with every cell division. This erosion 
is a result of the end-replication problem in eukaryotes, where conventional DNA polymerases 
are unable to synthesize in the 3’-5’ direction.[130, 133] Due to this mechanism, telomere 
degradation is strongly correlated with increased age.[134] However, there is considerable inter-
individual variation of telomere length based upon hereditary and environmental factors. Similar 
to inflammation, telomere length is influenced by a host of lifestyle factors, including physical 
inactivity, obesity, smoking behavior, alcohol use, and diet.[135-139] 
Colorectal cancer risk has been associated with telomere dysfunction in colon epithelial 
cells and circulating leukocytes, with both long and short telomeres implicated in colorectal 
cancer occurrence.[140-144] However, a recent study suggested this bimodal association is a 
result of the age of onset of colorectal cancer; young individuals with longer telomeres and older 
individuals with shorter telomeres were both found to be at increased risk of colorectal cancer 
development.[145] Given that the majority of colorectal cancer occurs in older individuals, 
telomere length shortening is most consistently linked to colorectal cancer incidence and 




as potential biomarkers for assessing colorectal cancer risk, diagnosis, and progression.[143, 
148-151]  
Additionally, telomere erosion in colonic epithelial cells can play a pivotal role in the 
early stages of colorectal carcinogenesis through triggering chromosomal instability.[152-154] 
This effect is quite significant given chromosomal instability is observed in 65-70% of sporadic 
colorectal cancer cases.[155] Typically, when telomeres in healthy cells reach a critically short 
length, termed the Hayflick limit, replicative senescence and apoptosis occur, and through this 
process, tumorigenesis is inhibited.[156-158] However, if severe telomere dysfunction precedes 
activation of cell cycle arrest, or tumor suppressive mechanisms such as p53 are compromised, 
continued mitosis causes progressive telomere degradation and results in the complete loss of 
one or more telomeres.[152, 155] Genomic instability subsequently ensues through chromosomal 
aberrations caused by end-to-end fusions and a succession of breakage-fusion-bridge 
cycles.[159] This process produces gross chromosomal instability and thus demonstrates the 
direct mechanistic effect that telomere length degradation within colon cells can play in the 
initiation of colorectal cancer.[152, 160, 161]  
Conversely, shorter leukocyte telomere length has not been directly implicated in the 
promotion of colorectal cancer. Leukocyte telomere length is indicative of an individual’s 
relative degree of biological aging, and considerable evidence suggests a strong correlation 
between chronic systemic inflammation and shortened telomere length.[162, 163] 
Correspondingly, leukocyte telomere length has been associated with increased risk of 
inflammation-associated colorectal cancer, and significant leukocyte telomere attrition in 
colorectal cancer patients is frequently accompanied by immune dysregulation and decreased 




been implicated as a potential biomarker for the likelihood of colorectal cancer development and 
prognosis.[143, 148]  
 
1.3  Colorectal cancer and diet 
The effect of poor diet on increased colorectal cancer risk is well demonstrated, and in 
particular, the Western diet, with high levels of consumption of refined carbohydrates and 
processed meat, is linked with increased cancer risk.[165] Given this finding, it is no surprise 
that multiple studies have demonstrated the effectiveness of diet modulation and 
supplementation in the reduction of chronic inflammation and colorectal cancer risk.[166-176]  
Specifically, there is strong evidence to support decreased risk of colorectal cancer with 
the consumption of unrefined grains and legumes.[177-183] The chemoprevention ability of 
grains and legumes is primarily attributed to these foods’ high dietary fiber content.[183-185] 
The phytochemical and antioxidant content of grains and legumes may also play a role in the 
prevention of colorectal cancer but this association is less established.[186-190] 
Dietary fiber refers to a diverse group of plant carbohydrates that resist digestion and 
absorption in the small intestine and undergo fermentation into short-chain fatty acids in the 
colon.[191, 192] Dietary fiber helps prevent colonic tissue injury from chronic inflammation by 
serving as a nutrition source for the microorganisms that protect intestinal epithelial cells.[193] 
Additionally, fermentation of dietary fiber results in decreased colonic inflammation through the 
inhibitory effects of short-chain fatty acids on chemokines such as interleukin-8 and on pro-
inflammatory cytokines such as tumor necrosis factor.[194-196] An inverse association between 




The high phytochemical and antioxidant content of grains and legumes also contributes to 
their anti-inflammatory and anti-neoplastic properties. For example, rice bran, the outer layer of 
the rice grain (Oryza spp.), possesses several bioactive components, such as γ-oryzanol, ferulic 
acid, tocopherols/tocotrienols, and tricin, that are known to have antioxidant and anti-
inflammatory effects.[199, 200] Similarly, common beans (Phaseolus vulgaris L.) have high 
concentrations of bioactive phenolic compounds, such as catechin, ferulic acid, p-Coumaric acid, 
kaempferol, β-Carotene, and γ-Tocopherol, which exhibit anti-inflammatory properties.[201]  
In relation to colorectal cancer, recent nutritional studies have identified rice bran and 
navy beans as foods with potential for chemoprevention.[199, 202-204] Animal studies have also 
demonstrated the ability of these foods to decrease both local and systemic biomarkers of 
inflammation and improve colonic health.[205-208] Given the evidence for these foods’ anti-
inflammatory and anti-neoplastic effects, this study evaluated their ability to modulate markers 




























2.1 Study samples 
 A total of 40 healthy individuals were evaluated in this study, and within this population, 
two cohorts were separately classified based upon whether or not they possessed a past medical 
history of colorectal cancer. The cohort of individuals with a history of colorectal cancer was 
comprised of seventeen females and twelve males, and the cohort without a history of colorectal 
cancer consisted of eight females and three males.  
Each study participant was randomly assigned to either a control, navy bean, or rice bran 
dietary intervention group, and during the 28 day study, participants consumed one meal and one 
snack specially designed to provide a daily dietary treatment of either 35 g of navy bean powder, 
30 g of rice bran, or a placebo control. Other than substituting one meal and one snack per day, 
participants were not asked to modify their previous dietary habits.   
For the cohort of individuals with a history of colorectal cancer, ten individuals were 
assigned to a control diet, ten individuals were assigned to a navy bean diet, and nine individuals 
were assigned to a rice bran diet. For the eleven total individuals without a history of colorectal 
cancer, three individuals were in the control group, four individuals were in the navy bean group, 
and three individuals were in the rice bran group. 
Study participants with a history of colorectal cancer were confirmed to have not 
undergone chemotherapy or radiation therapy within the last four months and all volunteers in 
the study had no history of any other form of cancer. Participants also did not have a history of 




denied any current tobacco use or the use within the last month of any prescription antibiotics. 





Figure 1: Study participant randomization flow chart. All individuals were healthy volunteers who participated in a 28-day 
dietary intervention trial. Participants were randomized by age, BMI, and total daily caloric intake into a control, navy bean (35 
g/day), and rice bran (30 g/day) supplementation treatment group. Each individual consumed one meal and one snack per day 
that contained the dietary treatment. Otherwise, participants’ diets were not restricted in any other manner and were allowed to 
consume any other foods they desired. Each participant completed a three-day food journal at three separate periods during the 









2.2 Blood collection and processing 
 Whole blood samples were collected from all study participants by a licensed 
phlebotomist on day 0, day 14, and day 28 of the study. Prior to blood collection, all participants 
fasted for at least eight hours to eliminate any effects of recent food intake on serum lipid profile. 
While lipid levels were measured in an outside clinical laboratory, all other blood component 
analysis was performed at Colorado State University within the respective laboratories of Dr. 
Elizabeth Ryan or Dr. Susan Bailey.  
After collection, plasma samples were isolated by centrifugation with EDTA and stored 
at -80°C in Mr. Frosty Freezing Containers filled with isopropyl alcohol. Samples were thawed 
on ice immediately prior to the cytokine immunoassay, and all samples analyzed had not 
previously been thawed since collection. 
Leukocytes were isolated by centrifugation using Cell Preparation Tubes (CPT) (BD 
Biosciences) with sodium citrate. Leukocyte samples were rinsed in 1X phosphate buffered 
saline (PBS), suspended in cell freezing media (10% DMSO: 90% FBS), and cryopreserved in 
liquid nitrogen vapor. Prior to telomere length measurement, leukocytes were thawed, rinsed in 
1X PBS, counted, and split into separate fractions for telomere length measurement by both 
quantitative polymerase chain reaction and interphase fluorescence in situ hybridization. 
 
2.3 Cytokine immunoassay  
The cytokines IL-2, IL-4, IL-6, IL-8, IL-10, and TNF were measured in the plasma of a 
total of eleven individuals without a history of colorectal cancer and 23 individuals with a history 
of colorectal cancer. VEGF concentrations were also obtained from 23 participants with a history 




cancer were excluded from analysis as the quality control for this analyte fell outside of the 
acceptable range for quality assay performance. Quality controls for all other analytes were 
within acceptable range.  
Plasma cytokine levels were measured using the Milliplex® MAP Human 
Cytokine/Chemokine Magnetic Bead Panel Immunoassay. Non-diluted plasma samples were 
prepared for analysis in a 96 well plate following the specific protocol provided by Millipore. 
Analytes were quantified using a MagPix analytical test instrument, which utilizes xMAP 
technology (Luminex Corp., Austin, TX) and xPONENT software (Luminex). The xMAP 
technology uses fluorescent magnetic beads coated with analyte specific capture antibodies to 
simultaneously measure multiple analytes in a sample. After the beads have captured the analyte, 
a biotinylated detection antibody binds to the complex. Streptavidin PE binds as a reporter 
molecule. Inside the Luminex instrument, magnetic beads are held in a monolayer by a magnet 
and two LEDs are used to excite the internal bead dye and the reporter molecule. Fluorescence 
intensity is measured by an internal charge coupled device camera, and mean fluorescence 
intensity (MFI) is recorded per well. Minimum bead count for acceptable fluorescence was set at 
50 beads per well. Cytokine concentrations (pg/mL) were based on a six point standard curve 
generated for each cytokine. A weighted 5-parameter logistic (5-PL) equation was fitted to MFI 
values for a 1:5 dilution series ranging from 3.2 – 10,000 pg/mL. The coefficient of 
determination (R
2
) for each standard curve ranged from 0.9902 to 0.9999 with an average of 
0.9978. Each plasma sample was measured in duplicate. Duplicate MFI’s were averaged and an 






The 5-PL equation is:  









a= MFI for minimal asymptote  
b= MFI for maximum asymptote 
c= concentration at inflection point (concentration at 50% maximum MFI) 
d= slope factor 
f= asymmetry factor 
 
2.4 Interphase quantitative fluorescence in situ hybridization (IQ-FISH) 
Telomere length was also quantified using Interphase Quantitative Fluorescence In Situ 
Hybridization (IQ-FISH). The preferred approach for measuring telomeres by FISH is on 
metaphase chromosomes. However, this technique requires actively dividing cells and was not 
suitable for the available cryopreserved samples. Additionally, leukocytes have varying mitotic 
indices between cell type, and after multiple passages, cultured leukocyte samples would likely 
have different cell population ratios than freshly drawn samples. 
IQ-FISH is a technique used for the visualization of interphase nuclei and was used to 
estimate relative telomere length of fixed leukocytes.[209] After leukocyte isolation and 
separation of cells into respective qPCR and IQ-FISH fractions, the IQ-FISH fraction was fixed 
in 3:1 methanol and stored at -20°C. At time of hybridization, leukocytes fixed in 
methanol:acetic acid were dropped on StarFrost® microscope slides and cell density was 
checked by microscope. Fixed cell suspensions were treated with 200 µl of 100 mg/ml RNase A, 
150 nM NaCl, and 15 mM sodium citrate at 37°C for 1 hour and 15 minutes. Slides were rinsed 
twice in 1X PBS for 5 min each, dehydrated through a graded ethanol series (75%, 80%, 100%) 
for 2 min each, denatured in 70% formamide/2X saline-sodium citrate (SSC) for 2.5 min at 
37°C, and dehydrated again through a graded ethanol series (75%, 80%, 100%) for 2 min each, 




formamide, 12 µL 0.05M Tris-HCl, 2.5 µL 0.1 M KCl, 0.6 µL 0.1M MgCl2 and 0.15 µL PNA 
probe. Fifty microliters of probe hybridization mix were applied to each sample and incubated in 
the dark at 37° C for 24 hours.  
After probe hybridization, slides were treated with a series of washes consisting of 50% 
formamide/2XSSC, 2X SSC, and 2X SSC with 0.1% Tergitol type NP40 detergent. After drying, 
slides were counterstained with 50µl DAPI, which is specific for AT rich sequences that 
dominate in non-telomeric DNA. Counter-stained slides were cover slipped and stored at -20°C 
until image analysis.  
Two-dimensional (2-D) image acquisition was performed on all available samples. A 
minimum of 50 images was obtained per respective fluorophore excitation camera filter (DAPI 
and TRITC) for 2-dimensional (2-D) image analysis. Three-dimensional (3-D) image acquisition 
was also performed on selected samples for analysis of variations between Cy3 and TRITC filter 
excitation spectrums. In 3-D image acquisition, 26 Z-axis images were taken in 0.2 µm segments 
with both DAPI and Cy3 filters. These images were then reconstructed to form a 2-D image. 
Conversion of 2-D image pixels to relative numerical values for telomere fluorescence intensity 
(TFI) was performed using TELOMETER, an ImageJ software plug-in designed for interphase 
FISH on telomeres.  
Telomere length was measured by IQ-FISH in a total of twenty individuals with a history 
of colorectal cancer, and for each individual, telomere length was measured at day 0, day 14, and 
day 28 of the study. The twenty individuals were randomly separated into three parallel batches 
due to limits within the number of samples that could be processed at a single time. The Raji cell 
line, a cultured line of human B-lymphocytes, and the LY-S cell line, a cultured line of mouse 




Ultimately, inter-batch comparison of telomere length measured by IQ-FISH was 
complicated by variability in results that was dependent on whether sample mean fluorescence 
intensities were normalized to the Raji or LY-S control cell lines. For the Raji control cell line, 
mean fluorescence intensities were highest in batch one (33.53) followed by batch two (25.11) 
and then batch three (19.87). A similar trend was observed for the LY-S control cell line where 
mean fluorescence intensities were highest in batch one (32.47) followed by batch two (30.96) 
and then batch three (14.32). However, when normalized to the Raji cell line, the average mean 
fluorescence intensities for individuals in batches one, two, and three were 1.69, 2.21, and 1.67, 
respectively. Whereas, when normalized to the LY-S cell line, the average mean fluorescence 
intensities for individuals in batches one, two, and three were 1.75, 1.79, and 2.03, respectively. 
Therefore, depending on which control cell line results were normalized to, the batch with the 
longest average telomere length could be either batch three or batch two. Given these conflicting 
results, it was decided to only analyze IQ-FISH telomere length measurements as separate, non-
comparable batches. Unfortunately, this significantly limited the sample sizes for the IQ-FISH 
telomere length data and thus negatively impacted the utility of this data.  
 
2.5 Telomere length measurement by singleplex qPCR  
Singleplex quantitative polymerase chain reaction (qPCR) was used to calculate the 
relative leukocyte telomere length of twenty-two study participants with a history of colorectal 
cancer, and for each individual, telomere length was measured using singleplex qPCR at day 0, 
day 14, and day 28 of the study. The twenty-two individuals were randomly separated into two 
groups due to limits within the number of samples that could fit on a single qPCR plate, and the 




The singleplex qPCR method estimates the average telomere length per individual by 
quantifying the ratio of telomere repeat copy number (T) to single copy housekeeping gene (S) in 
a sample.[210] The 36B4 gene, which encodes an acidic ribosomal phosphoprotein, was used as 
the housekeeping gene, and the telomere and 36B4 reactions were performed in separate wells 
with the same amount of sample DNA (20 ng). Reaction efficiencies were determined by the 
slope of a standard curve of 1.68-fold serially diluted Raji cell line DNA ranging from 100 ng to 
7.47 ng total DNA. Additionally, reaction efficiency was estimated in each individual reaction 
well using LinRegPCR (version 12.18). LinRegPCR is a software program that estimates 
individual PCR reaction efficiencies using the slope of the log-linear phase of the reaction’s 
amplification curve, and the program has been shown to reduce variability in qPCR results.[211] 
The relative starting concentration (N0) of each sample was calculated by LinRegPCR via the 
threshold level of the PCR amplification curve (Nq) and the cycle threshold (Cq) using the 
formula: 





Individual telomere length was estimated by the ratio: 
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 for each individual 
sample, and relative telomere length was determined by dividing each sample by the average 
telomere length of all individuals on a single plate. Finally, inter-plate comparison was attempted 
by normalizing each sample’s relative telomere length to the relative telomere length of the Raji 
control cell line, which was measured on each plate. 





Blood & Tissue Kit. Isolated genomic DNA was quantified using the 
spectrophotometer function of a Biotek
TM






Data Collection and Analysis Software. DNA purity was assessed by the 
A260/280 ratio with samples not within 1.8-2.0 excluded from analysis. Prior to qPCR, DNA 
was stored at -20 C in Tris-EDTA buffer (10 mM Tris-HCl, 0.5 mM EDTA; pH 9.0).  
DNA was amplified in 20µl singleplex qPCR reactions on a 384-well plate using a Roche 
LightCycler
®





 Green I Master Mix (2x), 2 µL of telomere or 36B4 primers (1 µL reverse, 1 µL 
forward), 20 ng DNA, and PCR grade water. All samples were run in triplicate. Primers were 
obtained from Integrated DNA Technologies, Inc. (IDT). Telomere and 36B4 primer pairs used 
for singleplex qPCR had the following respective sequences:   
tel1 5’-GGT TTT TGA GGG TGA GGG TGA GGG TGA GGG TGA GGG T-3’ 
tel2 5’-TCC CGA CTA TCC CTA TCC CTA TCC CTA TCC CTA TCC CTA-3’ 
36B4F 5’-CAG CAA GTG GGA AGG TGT AAT CC-3’ 
36B4R 5’-CCC ATT CTA TCA TCA ACG GGT ACA A-3’ 
The thermal cycling profile was: 10 min at 95°C, followed by 45 cycles of 95°C for 10 
sec, 54°C for 1 min, and a melt dissociation curve.  
Based off a standard curve of serially diluted Raji cell line DNA, reaction efficiencies for 
the 36B4 reaction were 98.5% for plate one and 100.7% for plate two, with a coefficient of 
determination, R
2
, of 0.995 for both plates. When analyzed on a per-well basis using LinRegPCR 
software, the average reaction efficiency for the 36B4 primer set was 90.0% for plate one and 
92.1% for plate two. For the tel1/tel2 primer pair, reaction efficiencies based off a Raji cell line 
standard curve were 66.7% for plate one and 65.0% for plate two, with an R
2
 value of 0.875 and 
0.830, respectively. Using LinRegPCR, reaction efficiencies for the tel1/tel2 primer set were 




For the 36B4 primer set, coefficient of variation values for the cycle thresholds of 
triplicate individual samples ranged from 0.02% to 0.51% with a mean value of 0.20%. The 
coefficient of variation for the cycle thresholds of triplicate individual samples amplified with 
tel1/tel2 ranged from 0.01% to 1.98% with a mean value of 0.83%. For the Raji cell line, which 
was used as a control for normalization between the two plates, the coefficient of variation for 
the cycle thresholds of the triplicate samples amplified with 36B4 primers was 0.04% and 
0.06%. For the tel1/tel2 primer set, Raji cell line triplicate samples had a coefficient of variation 
of 7.43% for plate one and 3.49% for plate two. Finally, the estimated individual telomere 
lengths of the Raji control samples had a coefficient of variation of 68.8%. For both plates, 
graphs of the derivative melt dissociation curve for the 36B4 primer set showed a single peak 
with an approximate melting temperature of 80.5°C. 
Ultimately, telomere length measured by singleplex qPCR was determined to be 
unreliable due to non-specific product amplification. Not only were efficiencies of the tel1/tel2 
reactions markedly less than 90%, but also 165 out of 198 distinct samples had tel1/tel2 melt 
dissociation curves with two peaks (one at approximately 80.0°C and another at 82.5°C). 
Additionally, melt dissociation curves of the no template control reactions for the tel1/tel2 primer 
set showed a small, broad elevation in derivative fluorescence ranging from approximately 
78.0°C to 80.0°C. Non-specific product formation was likely a result of primer-dimerization 
given the shorter product (80.0°C) was very close to the estimated salt-adjusted melting 
temperature of the tel2 primer (78.8°C).[212] Due to the non-specific product amplification by 
the tel1/tel2 primers, a separate protocol for telomere length measurement by qPCR was 
performed.  




2.6 Telomere length measurement by monochrome multiplex qPCR  
 Relative leukocyte telomere length was estimated in twenty-seven study participants with 
a history of colorectal cancer using a monochrome multiplex qPCR method, and for each 
individual, telomere length was measured using multiplex qPCR at day 0 and day 28 of the 
study. This experiment was performed by Lynn Taylor of Dr. Bailey’s lab. The multiplex qPCR 
method for telomere length measurement is similar in concept and protocol to the singleplex 
method except that all reactions occur within a single well and a different set of telomere and 
housekeeping gene primers are used.[213]  
 Sample DNA was isolated by the same protocol as the singleplex method. Each multiplex 
qPCR reaction had a total volume of 25 µL and consisted of 1X GoTaq qPCR Master Mix 
(Promega), 900 nM telg and telc telomere primers, 400 nM albu and albd albumin primers, and 
10 ng genomic DNA. The telomere and albumin primers used for multiplex qPCR were:  
telg 5’-ACA CTA AGG TTT GGG TTT GGG TTT GGG TTT GGG TTA GTG T-3’  
telc 5’-TGT TAG GTA TCC CTA TCC CTA TCC CTA TCC CTA TCC CTA ACA-3’ 
albu 5’-CGG CGG CGG GCG GCG CGG GCT GGG CGG AAA TGC TGC ACA GAA TCC TTG-3’ 
albd 5’-GCC CGG CCC GCC GCG CCC GTC CCG CCG GAA AAG CAT GGT CGC CTG TT-3’ 
DNA was amplified in a BioRad CFX96/C1000 Thermal Cycling System with the 
following two-stage thermal cycling profile: Stage 1: 15 min at 95°C; Stage 2: 2 cycles of 15 s at 
94°C, 15 s at 49°C; and Stage 3: 32 cycles of 15 s at 94°C, 10 s at 62°C, 15 s at 74°C with signal 
acquisition, 10 s at 84°C, 15 s at 88°C with signal acquisition. Reaction efficiencies were 
assessed using standard curves created from a 3-fold serial dilution of human genomic DNA 
ranging from 50 ng to 0.62 ng. Similar to the singleplex qPCR method, individual telomere 







 for each individual sample. However, instead of LinRegPCR, another 
similar software program, CFX Manager™ Software, was used. Relative telomere length was 
determined by dividing each sample by the average telomere length of the triplicate human 
genomic DNA that was used as a control on each plate.  
For the albu/albd primers, reaction efficiencies based off the respective standard curves 
for plates one, two, and three were 100.1%, 95.2%, and 97.3%, with R
2
 values of 0.999, 0.997, 
and 0.998. For the telg/telc primers, reaction efficiencies for plates one, two, and three were 
112.9%, 107.7%, and 105.5%, with R
2
 values of 0.998, 0.998, and 0.995.  
 The coefficient of variation for the cycle thresholds of triplicate individual samples 
amplified with the albu/albd primers ranged from 0.05% to 0.81% with a mean value of 0.30%. 
For the telg/telc primer set, coefficient of variation for triplicate cycle threshold values ranged 
from 0.08% to 1.48% with a mean value of 0.54%.  
 In contrast to the Raji cell line DNA used for the singleplex method, the human genomic 
DNA standard was found to have consistent individual telomere lengths across all three plates. 
The coefficient of variation between all three plates was 5.06%. Additionally, melt dissociation 
curves for the multiplex telomere data indicated a single peak for both the telg/telc and the 
albu/albd primer pairs. No amplification was observed in the no template controls.  
 
2.7  Nutrient data collection 
 Each participant’s daily nutrient intake was estimated through using individual, self-
reported total food and beverage consumption habits. Each participant recorded a dietary food 
journal of their consumption behavior over a three-day span at three separate time points of the 






, to obtain estimates of each individual’s nutrient consumption. Specifically, 
data was obtained for total daily intake of several minerals (calcium, iron, magnesium, 
potassium, selenium, sodium, and zinc), vitamins (A, β-carotene, B1, B2, B3, B6, B9, B12, C, D, 
E, and α-Tocopherol), macronutrients (carbohydrates, protein, total fat, and saturated fat), 
unsaturated fatty acids (oleic, linoleic, and linolenic) and fiber. This data was then used for 
correlation analysis with telomere length and cytokine concentrations.  
 
2.8 Statistical analysis 
2.8.1 Descriptive statistics 
All statistical analysis was performed with cloud-based SAS University Edition software 
through the use of VMWare Fusion virtualization software. Descriptive statistics for all study 
variables are reported separately for the two study cohorts: participants with a history of 
colorectal cancer and participants without a history of colorectal cancer. Additionally, 
descriptive statistics within each dietary intervention group and by sex are reported for 
participants with a history of colorectal cancer. 
 
2.8.2 Normality testing 
 The distribution of each variable within the two study cohorts was assessed for normality 
using the Shapiro-Wilk (S-W) and Anderson-Darling (A-D) tests. Of these tests, the S-W test is 
considered to provide better statistical power and to be more appropriate for small sample sizes 
(n < 30).[214] However, the A-D test, a non-parametric, goodness-of-fit test, is an acceptable 




logarithm transformation was performed prior to statistical analysis. Additionally, distribution 
and probability plots were created to visually assess for normality prior to data analysis.  
 
2.8.3 Cytokine statistical analysis 
Immunological data acquisition and analysis is often restricted by the levels of detection 
(LOD) of the immunoassay’s standard curve. In general, serum cytokine concentrations are 
relatively low and transient. Therefore, it is not uncommon to have cytokine MFI values that fall 
below the lowest level of detection (LLOD) of the standard curve. In this situation, population 
data is “left-censored”, meaning the exact value of some observations are missing but known to 
fall within a range between zero and the LLOD. Several methods are available and frequently 
used to deal with left-censored immunological data, the most common of which are deletion, 
substitution, extrapolation, regression, and multiple imputation.[216, 217] These five approaches 
were applied and compared in this study.  
The first approach, list-wise deletion, ignored all samples with concentrations below the 
LLOD (3.2 pg/ml). Linear regression analysis by time point and diet group was performed on a 
strict data set comprised of concentration values falling between the standard curve range of 3.2 
pg/ml to 10,000 pg/ml. Benefits of this approach include its simplicity and the overall confidence 
in observed values.[218] However, deletion reduces statistical power and can produce 
significantly biased results. For these reasons, the deletion method is not well suited for small 
sample sizes with missing data.  
The second approach applied a substitution method to values below the LLOD. Missing 
observations were substituted with a fixed value of LOD/2 (1.6 pg/ml) prior to linear regression 




However, substitution limits population variability and can result in weakened estimates of 
correlation and covariance.   
The third approach extrapolated missing values using the standard curve’s 5-PL equation. 
Extrapolation allows for complete case data analysis and unlike substitution, does not artificially 
decrease variability. However, extrapolation is rather imprecise due to the near horizontal slope 
at the lower end of the sigmoidal 5-PL where small changes in MFI can result in drastic 
differences in estimated sample concentration.  
The fourth technique employed Tobit regression, a form of censored regression analysis, 
to estimate linear relationships of censored cytokine data by time point and diet group. The Tobit 
regression estimates a linear regression model for the observed data and assumes the same 
distribution of errors for censored values. The Tobit model is described by the relationship 
between the observed, censored variable, y, in terms of the latent variable, y
*
, and the censoring 





The latent variable, y
*
, is considered the true value and is defined by the linear relationship with 
an independent variable x in the equation: 
�∗ =  �� + � 
The regression coefficient, β, and the error term, u, are determined by maximum 
likelihood estimation (MLE) based off their linear relationship with the observed data. 
Specifically, MLE selects the value of β and u that would result in the highest probability of 
producing the observed values. Tobit regression is an effective and well-established method for 




constant variance across observations, which are rarely satisfied by immunological data.[220, 
221]  
 The final approach utilized multiple imputation (MI) to account for missing values. This 
technique assumes a similar distribution within censored values as in observed data and uses 
MLE to create a complete data set by estimating each missing value.[222] This process is 
repeated several times to create multiple data sets that are then each analyzed separately. 
Analysis results from each imputed data set are then combined. MI has consistently been 
demonstrated to produce unbiased results with missing data.[216, 219, 223] However, MI is not 
effective for data with small sample sizes or with high percentages of censoring as the 
distribution of observed values is more likely to not reflect the distribution of censored 
values.[221, 224, 225] Furthermore, similar to Tobit regression, MI assumes the data is normally 
distributed. 
 For several analytes, the concentration estimated from the MFI via the 5-PL standard 
curve fell outside the lowest level of detection (3.2 pg/ml). For individuals without a history of 
colorectal cancer (n=11), the primary analytes that were either undetectable or required 
extrapolation beyond the limits of the standard curve were IL-2 (n=4), IL-4 (n=5), IL-6 (n=6), 
and IL-10 (=n=5). A similar trend was seen in individuals with a history of colorectal cancer 
(n=23) with IL-2 (n=9), IL-4 (n=12), IL-6 (n=11), and IL-10 (n=9).   
 Across all three plates, values for each respective cytokine’s standard curve and quality 
controls were consistent and precise, which allowed for direct inter-plate comparison. For IL-2, 
the coefficient of variation of controls and standards ranged from 0.30% to 9.11% with an 
average of 2.85%. For IL-4, IL-6, and IL-8, the coefficients of variation of controls ranged from 




from 0.16% to 7.61% with an average of 2.77%, respectively. Similar trends were seen in the 
consistency of the controls and standards for IL-10, TNF, and VEGF, where each averaged a 
coefficient of variation of 2.87%, 2.67%, and 2.36%.   
 
2.8.4 Analysis of longitudinal, between diet group, and between cohort differences 
 For both cohorts, differences in study variables between the three dietary intervention 
groups and across the three time points of data collection were assessed for statistical 
significance using one-way analysis of variance (ANOVA). Additionally, both linear regression 
and a two-way ANOVA was performed on the cohort with a history of colorectal cancer to 
assess for differences between sexes as well as for the effect of sex and diet and the effect of sex 
and time point on the dependent study variables. Lastly, differences in dependent variables 
between the two cohorts were analyzed by linear regression.  
 Differences in non-transformed variables are reported in the respective unit for that 
variable. For transformed variables, relative differences between diet groups, time points, or 
cohorts are reported as a ratio of geometric means (RoGM). RoGM was obtained after back 
transformation of the difference of the transformed means of each variable. That is, if X1 and X2 








2.8.5 Linear correlation analysis 
Correlation between variables was estimated using a repeated measure within subjects 
correlation model. This model accounts for the lack of independence among the repeated 




one variable in an individual is associated with a similar change in another variable for that same 
individual. In the overwhelming majority of correlations, an unstructured covariance matrix was 
used for modeling covariation between measurements within a single subject. This covariance 
matrix assumes no pattern on the covariances, and it is recommended structure for longitudinal 
data from randomized clinical trials.[226] However, when this model did not fit the data, a 


























3.1 Differences in plasma cytokine levels within and between diet groups  
In regards to cytokine concentration, for participants without a history of colorectal 
cancer, no significant differences were seen between diet group or time point for any cytokine. 
Similarly, no significant differences were found between diet groups or time point for IL-2, IL-4, 
IL-6, IL-8, and IL-10 in participants with a history of colorectal cancer.  
At day 28, the navy bean group within the history of colorectal cancer cohort had 
significantly higher TNF concentrations compared to the control group (RoGM=1.53; 95% 
CI=[1.02, 2.31]; p=0.041). Within these two groups, no values were below the limits of detection 
of the standard curve, so censored data analysis was not required.  
VEGF concentration in the navy bean group at day 28 was also significantly greater than 
the control group when analyzed using the Tobit regression approach for censored data 
(RoGM=3.63; 95% CI=[1.09, 12.05]; p=0.036) but non-significantly greater when using the 
other approaches for handling censored data: substitution (RoGM=3.89; 95% CI=[0.91, 16.62]; 
p=0.065), extrapolation (RoGM=12.01; 95% CI=[0.62, 232.43]; p=0.096), and multiple 
imputation (RoGM=1.45; 95% CI=[0.83, 2.53]; p=0.183). Given that the Tobit regression 
approach has been shown to be the most unbiased method for handling censored data and that 
only one VEGF value was below the lowest level of detection in regards to the comparison of the 
navy bean and control groups at day 28, the obtained significant result is considered the most 







Figure 2: Graphs showing mean plasma concentration +/- standard error of the mean for IL-2, IL-4, IL-6, IL-8, and IL-10. No 






Figure 3: Graphs showing mean plasma concentration +/- standard error of the mean for TNF and VEGF. At day 28, both TNF 
and VEGF concentration in the navy bean diet group were significantly higher than in the control groups. No significant change 




Table 1: Differences in age, weight, and body mass index between diet groups (left) and between time points (right) for study 
participants without a history of colorectal cancer. Variables shown above: age (top), weight (middle), and body mass index 
(BMI; bottom). The control group (n=3) was observed to have a significantly higher average weight than both the navy bean 
(n=4) and rice bran (n=4) groups at all time points. However, this was not observed when comparing BMI. The control group 
was observed to have a significantly greater BMI than the rice bran group at day 0. Otherwise, no significant difference was 














Table 2: Differences in plasma interleukin-2 and interleukin-4 between diet groups (left) and between time points (right) for 
study participants without a history of colorectal cancer. Variables shown above: IL-2 with substituted censored values (top), IL-
2 with extrapolated censored values (second from top), IL-4 with substituted censored values (second from bottom), and IL-4 
with extrapolated censored values (bottom). No significant differences were observed in the displayed variables between 









Table 3: Differences in plasma interleukin-6 and interleukin-8 between diet groups (left) and between time points (right) for 
study participants without a history of colorectal cancer. Variables shown above: IL-6 with substituted censored values (top), IL-
6 with extrapolated censored values (second from top), IL-8 with substituted censored values (second from bottom), and IL-8 
with extrapolated censored values (bottom). No significant differences were observed in the displayed variables between 









Table 4: Differences in plasma interleukin-10 and tumor necrosis factor between diet groups (left) and between time points 
(right) for study participants without a history of colorectal cancer. Variables shown above: IL-10 with substituted censored 
values (top), IL-10 with extrapolated censored values (second from top), TNF with substituted censored values (second from 
bottom), and TNF with extrapolated censored values (bottom). No significant differences were observed in the displayed 











Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.43 3.98 0.06 34.57 0.802 Day 14 Day 0 1.33 2.32 0.17 10.45 0.744
Rice Bran Control 1.10 3.98 0.05 26.66 0.946 Day 28 Day 0 0.63 2.32 0.08 4.93 0.602
Navy Bean Rice Bran 1.30 3.59 0.07 24.76 0.844 Day 28 Day 14 0.47 2.32 0.06 3.70 0.406
Navy Bean Control 1.13 3.49 0.06 20.15 0.925 Day 14 Day 0 1.05 1.84 0.27 4.16 0.934
Rice Bran Control 0.82 3.49 0.05 14.69 0.880 Day 28 Day 0 0.77 1.84 0.19 3.04 0.678
Navy Bean Rice Bran 1.37 3.18 0.10 19.76 0.792 Day 28 Day 14 0.73 1.84 0.19 2.89 0.619
Navy Bean Control 1.75 3.76 0.08 37.10 0.684 Day 14 Day 0 0.996 6.08 0.02 59.10 0.998
Rice Bran Control 2.22 3.76 0.10 47.07 0.564 Day 28 Day 0 1.27 6.08 0.02 75.18 0.898
Navy Bean Rice Bran 0.79 3.41 0.05 13.33 0.851 Day 28 Day 14 1.27 6.08 0.02 75.46 0.897
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 0.33 19.08 0.00 299.81 0.720 Day 14 Day 0 1.11 6.48 0.01 107.05 0.958
Rice Bran Control 0.02 19.08 0.00 18.27 0.223 Day 28 Day 0 0.12 6.48 0.00 11.47 0.297
Navy Bean Rice Bran 16.41 15.33 0.03 8895.35 0.336 Day 28 Day 14 0.11 6.48 0.00 10.35 0.277
Navy Bean Control 1.13 10.42 0.01 251.26 0.960 Day 14 Day 0 3.75 7.64 0.04 372.19 0.532
Rice Bran Control 0.08 10.42 0.00 16.85 0.303 Day 28 Day 0 0.77 7.64 0.01 76.53 0.901
Navy Bean Rice Bran 14.91 8.76 0.10 2222.40 0.248 Day 28 Day 14 0.21 7.64 0.00 20.43 0.457
Navy Bean Control 2.17 24.36 0.00 3416.36 0.815 Day 14 Day 0 4.12 35.30 0.00 13076.59 0.700
Rice Bran Control 0.77 24.36 0.00 1218.49 0.938 Day 28 Day 0 4.51 35.30 0.00 14301.08 0.683
Navy Bean Rice Bran 2.80 19.22 0.00 2560.11 0.736 Day 28 Day 14 1.09 35.30 0.00 3469.64 0.981
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.34 2.06 0.26 7.09 0.692 Day 14 Day 0 0.97 1.35 0.47 2.03 0.934
Rice Bran Control 0.86 2.06 0.16 4.54 0.841 Day 28 Day 0 0.60 1.35 0.29 1.26 0.142
Navy Bean Rice Bran 1.56 1.95 0.34 7.28 0.523 Day 28 Day 14 0.62 1.35 0.30 1.29 0.160
Navy Bean Control 1.13 2.01 0.23 5.64 0.868 Day 14 Day 0 0.82 1.19 0.55 1.22 0.282
Rice Bran Control 1.00 2.01 0.20 4.98 0.995 Day 28 Day 0 0.82 1.19 0.55 1.22 0.279
Navy Bean Rice Bran 1.13 1.91 0.26 5.03 0.852 Day 28 Day 14 0.999 1.19 0.67 1.49 0.994
Navy Bean Control 1.82 1.75 0.50 6.63 0.315 Day 14 Day 0 1.13 2.62 0.13 9.98 0.904
Rice Bran Control 1.93 1.75 0.53 7.02 0.275 Day 28 Day 0 1.35 2.62 0.15 11.95 0.763
Navy Bean Rice Bran 0.94 1.68 0.29 3.12 0.915 Day 28 Day 14 1.20 2.62 0.14 10.61 0.856
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.34 1.98 0.28 6.50 0.676 Day 14 Day 0 0.97 1.35 0.47 2.03 0.934
Rice Bran Control 0.92 1.98 0.19 4.43 0.903 Day 28 Day 0 0.60 1.35 0.29 1.26 0.142
Navy Bean Rice Bran 1.47 1.88 0.34 6.30 0.562 Day 28 Day 14 0.62 1.35 0.30 1.29 0.160
Navy Bean Control 1.13 1.82 0.28 4.50 0.847 Day 14 Day 0 0.82 1.19 0.55 1.22 0.282
Rice Bran Control 1.16 1.82 0.29 4.64 0.809 Day 28 Day 0 0.82 1.19 0.55 1.22 0.279
Navy Bean Rice Bran 0.97 1.74 0.27 3.50 0.958 Day 28 Day 14 0.999 1.19 0.67 1.49 0.994
Navy Bean Control 1.82 1.75 0.50 6.63 0.315 Day 14 Day 0 1.23 2.44 0.16 9.24 0.819
Rice Bran Control 1.93 1.75 0.53 7.02 0.275 Day 28 Day 0 1.27 2.44 0.17 9.49 0.797
Navy Bean Rice Bran 0.94 1.68 0.29 3.12 0.915 Day 28 Day 14 1.03 2.44 0.14 7.69 0.978
Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Tumor Necrosis Factor (Extrapolation) by Time Point






Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-10 (Extrapolation) by Time Point






Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Tumor Necrosis Factor (Substitution) by Time Point






Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-10 (Substitution) by Time Point






Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                          
One-Way Analysis of Variance of Interleukin-10 (Substitution) by Diet Group






Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                          
One-Way Analysis of Variance of Interleukin-10 (Extrapolation) by Diet Group






Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                          
One-Way Analysis of Variance of Tumor Necrosis Factor (Substitution) by Diet Group






Parameter Estimates for Study Participants without a History of Colorectal Cancer:                                                                                                                                                          
One-Way Analysis of Variance of Tumor Necrosis Factor (Extrapolation) by Diet Group









Table 5: Differences in age, weight, and body mass index between diet groups (left) and between time points (right) for study 
participants with a history of colorectal cancer. Variables shown above: age (top), weight (middle), and body mass index (BMI; 
















Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control -5.60 5.15 -16.19 4.99 0.287 Day 14 Day 0 0.00 6.20 -12.73 12.73 1.000
Rice Bran Control -2.73 5.29 -13.61 8.15 0.610 Day 28 Day 0 0.10 6.20 -12.63 12.83 0.987
Navy Bean Rice Bran -2.87 5.29 -13.75 8.01 0.593 Day 28 Day 14 0.10 6.20 -12.63 12.83 0.987
Navy Bean Control -5.60 5.15 -16.19 4.99 0.287 Day 14 Day 0 0.00 5.32 -10.92 10.92 1.000
Rice Bran Control -2.73 5.29 -13.61 8.15 0.610 Day 28 Day 0 0.00 5.32 -10.92 10.92 1.000
Navy Bean Rice Bran -2.87 5.29 -13.75 8.01 0.593 Day 28 Day 14 0.00 5.32 -10.92 10.92 1.000
Navy Bean Control -5.70 5.17 -16.33 4.93 0.280 Day 14 Day 0 0.00 3.54 -7.31 7.31 1.000
Rice Bran Control -2.83 5.31 -13.75 8.09 0.598 Day 28 Day 0 0.00 3.54 -7.31 7.31 1.000
Navy Bean Rice Bran -2.87 5.31 -13.79 8.05 0.594 Day 28 Day 14 0.00 3.54 -7.31 7.31 1.000
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 2.35 8.11 -14.33 19.02 0.775 Day 14 Day 0 -0.34 7.54 -15.82 15.13 0.964
Rice Bran Control 6.89 8.34 -10.25 24.02 0.416 Day 28 Day 0 -0.54 7.54 -16.01 14.93 0.943
Navy Bean Rice Bran -4.54 8.34 -21.68 12.59 0.591 Day 28 Day 14 -0.20 7.54 -15.67 15.27 0.979
Navy Bean Control 2.66 8.11 -14.01 19.33 0.746 Day 14 Day 0 -0.03 9.05 -18.61 18.55 0.998
Rice Bran Control 6.01 8.33 -11.12 23.14 0.477 Day 28 Day 0 0.05 9.05 -18.53 18.63 0.996
Navy Bean Rice Bran -3.35 8.33 -20.48 13.78 0.691 Day 28 Day 14 0.08 9.05 -18.50 18.66 0.993
Navy Bean Control 2.94 8.19 -13.89 19.77 0.723 Day 14 Day 0 -1.22 8.10 -17.94 15.49 0.881
Rice Bran Control 6.86 8.41 -10.43 24.15 0.422 Day 28 Day 0 -0.57 8.10 -17.28 16.15 0.945
Navy Bean Rice Bran -3.92 8.41 -21.22 13.37 0.645 Day 28 Day 14 0.65 8.10 -16.06 17.37 0.936
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.22 2.61 -4.14 6.58 0.644 Day 14 Day 0 -0.11 1.45 -3.08 2.86 0.940
Rice Bran Control 1.48 2.68 -4.02 6.99 0.584 Day 28 Day 0 -0.16 1.45 -3.13 2.81 0.913
Navy Bean Rice Bran -0.26 2.68 -5.77 5.24 0.922 Day 28 Day 14 -0.05 1.45 -3.02 2.92 0.973
Navy Bean Control 1.32 2.62 -4.06 6.70 0.619 Day 14 Day 0 -0.01 3.62 -7.43 7.41 0.998
Rice Bran Control 1.21 2.69 -4.33 6.74 0.658 Day 28 Day 0 0.02 3.62 -7.40 7.44 0.996
Navy Bean Rice Bran 0.11 2.69 -5.42 5.65 0.966 Day 28 Day 14 0.03 3.62 -7.39 7.45 0.993
Navy Bean Control 1.40 2.67 -4.09 6.89 0.605 Day 14 Day 0 -0.39 2.46 -5.47 4.69 0.876
Rice Bran Control 1.49 2.75 -4.16 7.13 0.592 Day 28 Day 0 -0.16 2.46 -5.23 4.92 0.950
Navy Bean Rice Bran -0.09 2.75 -5.73 5.56 0.974 Day 28 Day 14 0.23 2.46 -4.84 5.31 0.925
































Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Age by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Age by Time Point
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Weight by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Weight by Time Point
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Body Mass Index by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           










Table 6: Differences in plasma interleukin-2 between diet groups (left) and between time points (right) for study participants 
with a history of colorectal cancer (n=23). Many study participants had IL-2 levels that were below the lowest level of detection 
of the cytokine immunoassay (39.1% at day 0, 43.4% at day 14, and 43.4% at day 28). Shown above are analyses of four 
different IL-2 data sets that each utilized a different approach for managing left-censored data. These approaches are: substitution 
with a fixed value (top), extrapolation using the 5-parametric logistic standard curve equation (second from top), Tobit regression 
(second from bottom), and multiple imputation (bottom). For all approaches, no significant difference was observed in plasma 










Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.49 1.75 0.46 4.82 0.483 Day 14 Day 0 0.90 1.67 0.31 2.58 0.831
Rice Bran Control 1.01 1.68 0.34 2.99 0.980 Day 28 Day 0 0.76 1.67 0.26 2.17 0.589
Navy Bean Rice Bran 1.47 1.78 0.44 4.90 0.508 Day 28 Day 14 0.84 1.67 0.29 2.43 0.742
Navy Bean Control 1.51 1.75 0.47 4.88 0.468 Day 14 Day 0 0.91 1.64 0.32 2.60 0.847
Rice Bran Control 1.09 1.68 0.37 3.20 0.873 Day 28 Day 0 1.06 1.64 0.37 3.03 0.908
Navy Bean Rice Bran 1.39 1.78 0.42 4.62 0.571 Day 28 Day 14 1.17 1.64 0.41 3.34 0.758
Navy Bean Control 2.10 1.72 0.68 6.47 0.186 Day 14 Day 0 0.96 1.76 0.29 3.13 0.945
Rice Bran Control 1.28 1.65 0.45 3.62 0.626 Day 28 Day 0 0.95 1.76 0.29 3.11 0.934
Navy Bean Rice Bran 1.64 1.74 0.52 5.20 0.383 Day 28 Day 14 0.99 1.76 0.30 3.23 0.989
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 9.08 5.23 0.29 286.37 0.197 Day 14 Day 0 0.86 4.81 0.03 22.01 0.925
Rice Bran Control 0.44 4.60 0.02 10.66 0.599 Day 28 Day 0 0.88 4.81 0.03 22.40 0.934
Navy Bean Rice Bran 20.52 5.45 0.60 704.78 0.090 Day 28 Day 14 1.02 4.81 0.04 26.01 0.991
Navy Bean Control 8.94 4.83 0.33 239.01 0.180 Day 14 Day 0 0.85 2.74 0.10 7.25 0.872
Rice Bran Control 0.80 4.27 0.04 16.46 0.877 Day 28 Day 0 0.41 2.74 0.05 3.54 0.394
Navy Bean Rice Bran 11.23 5.02 0.39 325.83 0.150 Day 28 Day 14 0.49 2.74 0.06 4.17 0.487
Navy Bean Control 4.28 5.55 0.12 152.94 0.406 Day 14 Day 0 1.55 6.11 0.04 66.83 0.812
Rice Bran Control 0.81 4.86 0.03 21.76 0.893 Day 28 Day 0 1.60 6.11 0.04 68.89 0.799
Navy Bean Rice Bran 5.32 5.79 0.14 207.31 0.353 Day 28 Day 14 1.03 6.11 0.02 44.49 0.987
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.56 1.82 0.48 5.03 0.461 Day 14 Day 0 0.84 1.98 0.22 3.21 0.796
Rice Bran Control 1.01 1.77 0.33 3.08 0.985 Day 28 Day 0 0.68 1.99 0.17 2.61 0.569
Navy Bean Rice Bran 1.54 1.86 0.46 5.17 0.486 Day 28 Day 14 0.81 2.01 0.20 3.17 0.758
Navy Bean Control 1.66 1.90 0.47 5.83 0.430 Day 14 Day 0 0.90 1.50 0.41 2.00 0.805
Rice Bran Control 1.12 1.83 0.34 3.67 0.854 Day 28 Day 0 1.06 1.50 0.48 2.35 0.883
Navy Bean Rice Bran 1.48 1.92 0.41 5.31 0.544 Day 28 Day 14 1.17 1.50 0.53 2.60 0.693
Navy Bean Control 2.36 1.85 0.71 7.90 0.163 Day 14 Day 0 0.95 2.07 0.23 3.99 0.948
Rice Bran Control 1.37 1.79 0.44 4.28 0.594 Day 28 Day 0 0.94 2.08 0.23 3.95 0.938
Navy Bean Rice Bran 1.73 1.86 0.51 5.84 0.377 Day 28 Day 14 0.99 2.08 0.24 4.15 0.990
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.31 1.68 0.48 3.61 0.599 Day 14 Day 0 0.99 1.71 0.34 2.85 0.987
Rice Bran Control 1.22 1.66 0.45 3.30 0.697 Day 28 Day 0 0.62 1.80 0.19 2.02 0.421
Navy Bean Rice Bran 1.08 1.70 0.38 3.03 0.889 Day 28 Day 14 0.63 1.76 0.20 1.92 0.408
Navy Bean Control 1.22 1.57 0.50 2.98 0.657 Day 14 Day 0 0.92 1.54 0.40 2.14 0.855
Rice Bran Control 1.02 1.52 0.45 2.32 0.967 Day 28 Day 0 1.04 1.54 0.45 2.41 0.927
Navy Bean Rice Bran 1.20 1.59 0.49 2.98 0.690 Day 28 Day 14 1.12 1.54 0.48 2.62 0.785
Navy Bean Control 2.20 1.79 0.69 6.98 0.178 Day 14 Day 0 0.83 1.60 0.33 2.07 0.687
Rice Bran Control 1.67 1.71 0.58 4.83 0.337 Day 28 Day 0 0.85 1.60 0.34 2.13 0.731
Navy Bean Rice Bran 1.31 1.71 0.46 3.75 0.609 Day 28 Day 14 1.03 1.57 0.43 2.49 0.950
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-2 (Multiple Imputation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-2 (Multiple Imputation) by Time Point






Day 14 0.876 Navy Bean 0.951
Day 28 0.314 Rice Bran 0.898
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-2 (Tobit Regression) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-2 (Tobit Regression) by Time Point






Day 14 0.718 Navy Bean 0.924
Day 28 0.374 Rice Bran 0.997
0.996












Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-2 (Substitution) by Time Point
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-2 (Extrapolation) by Time Point
0.959






Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                         
One-Way Analysis of Variance of Interleukin-2 (Extrapolation) by Diet Group






Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                         




Table 7: Differences in plasma interleukin-4 between diet groups (left) and between time points (right) for study participants 
with a history of colorectal cancer (n=23). Many study participants had IL-4 levels that were below the lowest level of detection 
of the cytokine immunoassay (47.8% at day 0, 47.8% at day 14, and 47.8% at day 28). Shown above are analyses of four 
different IL-4 data sets that each utilized a different approach for managing left-censored data. These approaches are: substitution 
with a fixed value (top), extrapolation using the 5-parametric logistic standard curve equation (second from top), Tobit regression 
(second from bottom), and multiple imputation (bottom). For all approaches, no significant difference was observed in plasma 










Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.10 2.05 0.25 4.94 0.894 Day 14 Day 0 0.97 1.82 0.28 3.34 0.960
Rice Bran Control 1.12 1.94 0.28 4.47 0.865 Day 28 Day 0 0.83 1.82 0.24 2.87 0.763
Navy Bean Rice Bran 0.98 2.09 0.21 4.57 0.982 Day 28 Day 14 0.86 1.82 0.25 2.96 0.802
Navy Bean Control 1.52 1.98 0.37 6.34 0.545 Day 14 Day 0 1.34 2.27 0.23 7.68 0.726
Rice Bran Control 1.09 1.88 0.29 4.07 0.890 Day 28 Day 0 1.35 2.27 0.24 7.73 0.720
Navy Bean Rice Bran 1.39 2.01 0.32 6.01 0.640 Day 28 Day 14 1.01 2.27 0.18 5.77 0.994
Navy Bean Control 1.78 1.98 0.43 7.46 0.408 Day 14 Day 0 0.94 1.92 0.24 3.67 0.931
Rice Bran Control 1.32 1.88 0.35 4.92 0.668 Day 28 Day 0 0.98 1.92 0.25 3.80 0.973
Navy Bean Rice Bran 1.36 2.02 0.31 5.87 0.669 Day 28 Day 14 1.04 1.92 0.27 4.02 0.958
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 4.62 6.96 0.08 264.59 0.440 Day 14 Day 0 0.98 5.80 0.03 36.69 0.989
Rice Bran Control 0.82 5.99 0.02 34.38 0.914 Day 28 Day 0 0.83 5.80 0.02 31.11 0.915
Navy Bean Rice Bran 5.61 7.31 0.09 355.45 0.396 Day 28 Day 14 0.85 5.80 0.02 31.87 0.926
Navy Bean Control 4.85 6.94 0.09 275.36 0.425 Day 14 Day 0 1.02 5.79 0.02 43.35 0.989
Rice Bran Control 0.80 5.96 0.02 33.00 0.900 Day 28 Day 0 1.38 5.79 0.03 58.19 0.858
Navy Bean Rice Bran 6.09 7.27 0.10 382.14 0.374 Day 28 Day 14 1.34 5.79 0.03 56.78 0.869
Navy Bean Control 7.67 6.73 0.14 409.88 0.298 Day 14 Day 0 0.94 7.27 0.02 58.50 0.977
Rice Bran Control 0.97 5.80 0.02 38.07 0.987 Day 28 Day 0 0.98 7.27 0.02 60.58 0.991
Navy Bean Rice Bran 7.89 7.06 0.13 465.03 0.303 Day 28 Day 14 1.04 7.27 0.02 64.14 0.986
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.18 2.81 0.16 8.99 0.871 Day 14 Day 0 0.96 2.49 0.16 5.76 0.966
Rice Bran Control 1.21 2.60 0.19 7.85 0.843 Day 28 Day 0 0.79 2.50 0.13 4.79 0.801
Navy Bean Rice Bran 0.98 2.86 0.12 7.69 0.984 Day 28 Day 14 0.82 2.50 0.14 4.98 0.834
Navy Bean Control 1.83 2.43 0.32 10.43 0.497 Day 14 Day 0 1.51 2.61 0.23 9.84 0.669
Rice Bran Control 1.15 2.31 0.22 5.95 0.865 Day 28 Day 0 1.52 2.60 0.23 9.91 0.663
Navy Bean Rice Bran 1.59 2.47 0.27 9.29 0.610 Day 28 Day 14 1.01 2.55 0.16 6.30 0.994
Navy Bean Control 2.24 2.46 0.38 13.07 0.371 Day 14 Day 0 0.93 2.42 0.16 5.29 0.938
Rice Bran Control 1.46 2.33 0.28 7.68 0.657 Day 28 Day 0 0.97 2.42 0.17 5.51 0.976
Navy Bean Rice Bran 1.54 2.48 0.26 9.13 0.638 Day 28 Day 14 1.04 2.42 0.18 5.91 0.962
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 0.86 1.93 0.24 3.12 0.814 Day 14 Day 0 0.89 1.70 0.31 2.52 0.823
Rice Bran Control 1.09 1.86 0.32 3.68 0.887 Day 28 Day 0 0.64 1.72 0.22 1.86 0.415
Navy Bean Rice Bran 0.78 2.00 0.20 3.07 0.726 Day 28 Day 14 0.72 1.70 0.26 2.05 0.542
Navy Bean Control 1.20 1.79 0.38 3.75 0.754 Day 14 Day 0 1.24 2.19 0.27 5.76 0.780
Rice Bran Control 1.04 1.70 0.37 2.97 0.935 Day 28 Day 0 1.30 2.19 0.28 6.07 0.739
Navy Bean Rice Bran 1.15 1.80 0.36 3.65 0.814 Day 28 Day 14 1.04 2.15 0.23 4.67 0.954
Navy Bean Control 1.73 1.90 0.49 6.13 0.395 Day 14 Day 0 0.85 1.75 0.28 2.55 0.771
Rice Bran Control 1.44 1.82 0.44 4.68 0.546 Day 28 Day 0 0.85 1.75 0.28 2.53 0.765
Navy Bean Rice Bran 1.20 1.88 0.35 4.17 0.769 Day 28 Day 14 1.00 1.71 0.35 2.85 0.996
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-4 (Multiple Imputation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-4 (Multiple Imputation) by Time Point






Day 14 0.932 Navy Bean 0.913
Day 28 0.643 Rice Bran 0.934
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-4 (Tobit Regression) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-4 (Tobit Regression) by Time Point






Day 14 0.785 Navy Bean 0.885







Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-4 (Substitution) by Time Point
1.000
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                         
One-Way Analysis of Variance of Interleukin-4 (Substitution) by Diet Group












Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-4 (Extrapolation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-4 (Extrapolation) by Time Point
0.996










Table 8: Differences in plasma interleukin-6 between diet groups (left) and between time points (right) for study participants 
with a history of colorectal cancer (n=23). Many study participants had IL-6 levels that were below the lowest level of detection 
of the cytokine immunoassay (47.8% at day 0, 52.1% at day 14, and 52.1% at day 28). Shown above are analyses of four 
different IL-6 data sets that each utilized a different approach for managing left-censored data. These approaches are: substitution 
with a fixed value (top), extrapolation using the 5-parametric logistic standard curve equation (second from top), Tobit regression 
(second from bottom), and multiple imputation (bottom). For all approaches, no significant difference was observed in plasma 













Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.03 1.59 0.39 2.71 0.952 Day 14 Day 0 0.92 1.50 0.40 2.10 0.828
Rice Bran Control 0.97 1.53 0.40 2.36 0.938 Day 28 Day 0 0.75 1.50 0.33 1.72 0.481
Navy Bean Rice Bran 1.06 1.61 0.39 2.87 0.898 Day 28 Day 14 0.82 1.50 0.36 1.88 0.624
Navy Bean Control 1.05 1.60 0.39 2.80 0.920 Day 14 Day 0 0.93 1.75 0.28 3.09 0.904
Rice Bran Control 1.06 1.54 0.43 2.62 0.898 Day 28 Day 0 1.12 1.75 0.34 3.70 0.846
Navy Bean Rice Bran 0.99 1.62 0.36 2.72 0.986 Day 28 Day 14 1.20 1.75 0.36 3.97 0.753
Navy Bean Control 1.53 1.64 0.55 4.30 0.396 Day 14 Day 0 1.00 1.57 0.39 2.57 0.997
Rice Bran Control 1.53 1.58 0.59 3.95 0.364 Day 28 Day 0 1.18 1.57 0.46 3.03 0.714
Navy Bean Rice Bran 1.00 1.66 0.35 2.89 0.993 Day 28 Day 14 1.18 1.57 0.46 3.03 0.717
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 3.20 3.13 0.30 34.59 0.321 Day 14 Day 0 0.86 3.50 0.07 11.46 0.908
Rice Bran Control 1.01 2.87 0.11 9.12 0.989 Day 28 Day 0 0.57 3.50 0.04 7.62 0.662
Navy Bean Rice Bran 3.15 3.22 0.27 36.16 0.338 Day 28 Day 14 0.66 3.50 0.05 8.81 0.747
Navy Bean Control 3.80 3.26 0.32 44.65 0.271 Day 14 Day 0 1.03 1.94 0.25 4.21 0.967
Rice Bran Control 1.50 2.97 0.15 14.53 0.714 Day 28 Day 0 0.74 1.94 0.18 3.05 0.661
Navy Bean Rice Bran 2.54 3.35 0.20 31.64 0.451 Day 28 Day 14 0.72 1.94 0.18 2.96 0.632
Navy Bean Control 4.14 3.94 0.24 72.16 0.312 Day 14 Day 0 1.28 3.64 0.09 18.79 0.852
Rice Bran Control 1.58 3.54 0.11 22.10 0.720 Day 28 Day 0 0.90 3.64 0.06 13.19 0.934
Navy Bean Rice Bran 2.61 4.07 0.14 48.88 0.502 Day 28 Day 14 0.70 3.64 0.05 10.33 0.787
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.03 1.68 0.38 2.85 0.947 Day 14 Day 0 0.88 1.68 0.32 2.45 0.812
Rice Bran Control 0.96 1.61 0.38 2.45 0.932 Day 28 Day 0 0.66 1.72 0.23 1.90 0.436
Navy Bean Rice Bran 1.08 1.70 0.38 3.06 0.888 Day 28 Day 14 0.74 1.73 0.25 2.17 0.585
Navy Bean Control 1.07 1.78 0.35 3.31 0.908 Day 14 Day 0 0.92 1.90 0.26 3.23 0.896
Rice Bran Control 1.08 1.70 0.38 3.07 0.884 Day 28 Day 0 1.15 1.87 0.34 3.95 0.822
Navy Bean Rice Bran 0.99 1.80 0.31 3.12 0.986 Day 28 Day 14 1.25 1.88 0.36 4.31 0.720
Navy Bean Control 1.87 1.90 0.53 6.60 0.331 Day 14 Day 0 1.00 1.69 0.36 2.81 0.997
Rice Bran Control 1.82 1.83 0.56 5.93 0.319 Day 28 Day 0 1.22 1.69 0.44 3.41 0.698
Navy Bean Rice Bran 1.03 1.87 0.30 3.49 0.967 Day 28 Day 14 1.22 1.69 0.44 3.40 0.701
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.04 1.63 0.40 2.73 0.936 Day 14 Day 0 0.99 1.60 0.39 2.48 0.981
Rice Bran Control 1.16 1.58 0.47 2.85 0.749 Day 28 Day 0 0.56 1.75 0.18 1.72 0.300
Navy Bean Rice Bran 0.90 1.62 0.35 2.33 0.825 Day 28 Day 14 0.56 1.72 0.19 1.68 0.295
Navy Bean Control 1.03 1.52 0.45 2.34 0.950 Day 14 Day 0 0.98 1.73 0.33 2.86 0.965
Rice Bran Control 1.04 1.52 0.46 2.38 0.919 Day 28 Day 0 1.08 1.73 0.37 3.18 0.889
Navy Bean Rice Bran 0.98 1.58 0.40 2.43 0.972 Day 28 Day 14 1.11 1.69 0.40 3.08 0.847
Navy Bean Control 2.02 1.80 0.63 6.52 0.234 Day 14 Day 0 0.89 1.56 0.36 2.19 0.798
Rice Bran Control 2.37 1.80 0.71 7.89 0.153 Day 28 Day 0 1.14 1.47 0.53 2.44 0.739
Navy Bean Rice Bran 0.85 1.71 0.30 2.45 0.767 Day 28 Day 14 1.28 1.52 0.55 2.95 0.562
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Multiple Imputation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Multiple Imputation) by Time Point






Day 14 0.909 Navy Bean 0.910
Day 28 0.229 Rice Bran 0.720
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Tobit Regression) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Tobit Regression) by Time Point






Day 14 0.988 Navy Bean 0.936
Day 28 0.524 Rice Bran 0.905
0.962
0.913


















Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Substitution) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Substitution) by Time Point
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Extrapolation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-6 (Extrapolation) by Time Point









Table 9: Differences in plasma interleukin-8 between diet groups (left) and between time points (right) for study participants 
with a history of colorectal cancer (n=23). A few study participants had IL-8 levels that were below the lowest level of detection 
of the cytokine immunoassay (21.7% at day 0, 13.0% at day 14, and 13.0% at day 28). Shown above are analyses of four 
different IL-8 data sets that each utilized a different approach for managing left-censored data. These approaches are: substitution 
with a fixed value (top), extrapolation using the 5-parametric logistic standard curve equation (second from top), Tobit regression 
(second from bottom), and multiple imputation (bottom). For all approaches, no significant difference was observed in plasma 










Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.65 1.55 0.66 4.12 0.263 Day 14 Day 0 1.13 1.32 0.64 2.00 0.659
Rice Bran Control 0.76 1.50 0.33 1.77 0.507 Day 28 Day 0 0.86 1.32 0.49 1.52 0.589
Navy Bean Rice Bran 2.17 1.57 0.85 5.53 0.099 Day 28 Day 14 0.76 1.32 0.43 1.34 0.330
Navy Bean Control 1.08 1.41 0.53 2.21 0.820 Day 14 Day 0 0.74 1.50 0.31 1.76 0.471
Rice Bran Control 0.67 1.37 0.35 1.29 0.214 Day 28 Day 0 0.92 1.50 0.39 2.20 0.845
Navy Bean Rice Bran 1.62 1.42 0.78 3.38 0.183 Day 28 Day 14 1.25 1.50 0.52 2.97 0.596
Navy Bean Control 1.77 1.41 0.87 3.62 0.109 Day 14 Day 0 0.99 1.53 0.41 2.38 0.982
Rice Bran Control 0.91 1.37 0.47 1.76 0.776 Day 28 Day 0 1.03 1.53 0.43 2.48 0.944
Navy Bean Rice Bran 1.94 1.42 0.94 4.04 0.072 Day 28 Day 14 1.04 1.53 0.43 2.50 0.926
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 2.77 2.31 0.48 15.94 0.238 Day 14 Day 0 1.90 1.96 0.47 7.60 0.351
Rice Bran Control 1.30 2.17 0.26 6.53 0.736 Day 28 Day 0 1.22 1.96 0.30 4.89 0.770
Navy Bean Rice Bran 2.13 2.36 0.36 12.77 0.389 Day 28 Day 14 0.64 1.96 0.16 2.58 0.518
Navy Bean Control 1.08 1.35 0.58 2.04 0.797 Day 14 Day 0 0.74 1.50 0.31 1.76 0.471
Rice Bran Control 0.77 1.32 0.43 1.38 0.356 Day 28 Day 0 0.92 1.50 0.39 2.20 0.845
Navy Bean Rice Bran 1.41 1.36 0.74 2.69 0.282 Day 28 Day 14 1.25 1.50 0.52 2.97 0.596
Navy Bean Control 2.10 1.52 0.87 5.04 0.093 Day 14 Day 0 1.12 1.49 0.49 2.58 0.783
Rice Bran Control 1.18 1.47 0.53 2.65 0.673 Day 28 Day 0 1.11 1.49 0.48 2.55 0.805
Navy Bean Rice Bran 1.78 1.54 0.72 4.37 0.197 Day 28 Day 14 0.99 1.49 0.43 2.28 0.977
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.55 1.46 0.74 3.25 0.251 Day 14 Day 0 1.05 1.25 0.68 1.62 0.814
Rice Bran Control 0.78 1.43 0.39 1.58 0.491 Day 28 Day 0 0.81 1.24 0.53 1.23 0.327
Navy Bean Rice Bran 1.98 1.48 0.91 4.29 0.084 Day 28 Day 14 0.77 1.25 0.50 1.18 0.232
Navy Bean Control 1.04 1.34 0.58 1.86 0.892 Day 14 Day 0 0.74 1.45 0.36 1.53 0.418
Rice Bran Control 0.74 1.32 0.43 1.28 0.283 Day 28 Day 0 0.92 1.45 0.45 1.91 0.828
Navy Bean Rice Bran 1.41 1.35 0.78 2.54 0.258 Day 28 Day 14 1.25 1.45 0.60 2.58 0.553
Navy Bean Control 1.70 1.32 0.98 2.95 0.060 Day 14 Day 0 0.99 1.47 0.47 2.09 0.977
Rice Bran Control 0.96 1.30 0.57 1.61 0.887 Day 28 Day 0 1.00 1.46 0.48 2.11 0.998
Navy Bean Rice Bran 1.76 1.34 1.00 3.12 0.051 Day 28 Day 14 1.01 1.46 0.48 2.13 0.975
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.31 1.41 0.67 2.57 0.430 Day 14 Day 0 0.90 1.24 0.59 1.36 0.606
Rice Bran Control 0.83 1.39 0.43 1.58 0.566 Day 28 Day 0 0.71 1.24 0.47 1.08 0.111
Navy Bean Rice Bran 1.58 1.42 0.79 3.17 0.194 Day 28 Day 14 0.79 1.23 0.53 1.19 0.264
Navy Bean Control 1.08 1.34 0.61 1.92 0.776 Day 14 Day 0 0.74 1.50 0.31 1.76 0.471
Rice Bran Control 0.80 1.31 0.47 1.37 0.424 Day 28 Day 0 0.92 1.50 0.39 2.20 0.845
Navy Bean Rice Bran 1.35 1.35 0.74 2.44 0.325 Day 28 Day 14 1.25 1.50 0.52 2.97 0.596
Navy Bean Control 1.70 1.35 0.95 3.06 0.075 Day 14 Day 0 0.87 1.39 0.46 1.66 0.674
Rice Bran Control 0.97 1.32 0.56 1.68 0.923 Day 28 Day 0 0.84 1.39 0.44 1.59 0.583
Navy Bean Rice Bran 1.75 1.36 0.96 3.19 0.069 Day 28 Day 14 0.96 1.38 0.51 1.79 0.898
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-8 (Multiple Imputation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-8 (Multiple Imputation) by Time Point






Day 14 0.574 Navy Bean 0.750
Day 28 0.150 Rice Bran 0.836
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-8 (Tobit Regression) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-8 (Tobit Regression) by Time Point






Day 14 0.442 Navy Bean 0.704
Day 28 0.097 Rice Bran 0.999
0.954
0.995












Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-8 (Substitution) by Time Point






Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-8 (Extrapolation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-8 (Extrapolation) by Time Point






Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                         




Table 10: Differences in plasma interleukin-10 between diet groups (left) and between time points (right) for study participants 
with a history of colorectal cancer (n=23). Many study participants had IL-10 levels that were below the lowest level of detection 
of the cytokine immunoassay (39.1% at day 0, 34.8% at day 14, and 43.5% at day 28). Shown above are analyses of four 
different IL-10 data sets that each utilized a different approach for managing left-censored data. These approaches are: 
substitution with a fixed value (top), extrapolation using the 5-parametric logistic standard curve equation (second from top), 
Tobit regression (second from bottom), and multiple imputation (bottom). For all approaches, no significant difference was 











Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.61 1.88 0.43 6.02 0.457 Day 14 Day 0 1.03 1.73 0.33 3.19 0.960
Rice Bran Control 1.09 1.79 0.32 3.66 0.886 Day 28 Day 0 0.78 1.73 0.25 2.40 0.646
Navy Bean Rice Bran 1.48 1.91 0.39 5.71 0.548 Day 28 Day 14 0.75 1.73 0.24 2.34 0.611
Navy Bean Control 1.31 1.86 0.36 4.77 0.668 Day 14 Day 0 0.83 1.84 0.23 3.07 0.771
Rice Bran Control 1.08 1.77 0.33 3.55 0.896 Day 28 Day 0 0.90 1.84 0.24 3.30 0.863
Navy Bean Rice Bran 1.21 1.89 0.32 4.57 0.762 Day 28 Day 14 1.08 1.84 0.29 3.95 0.906
Navy Bean Control 1.87 1.89 0.50 7.06 0.337 Day 14 Day 0 1.02 1.93 0.26 4.00 0.977
Rice Bran Control 1.40 1.80 0.41 4.77 0.572 Day 28 Day 0 1.00 1.93 0.25 3.91 0.998
Navy Bean Rice Bran 1.33 1.92 0.34 5.20 0.663 Day 28 Day 14 0.98 1.93 0.25 3.84 0.975
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 5.50 4.58 0.23 131.55 0.276 Day 14 Day 0 0.81 4.47 0.04 17.72 0.886
Rice Bran Control 0.57 4.07 0.03 10.59 0.690 Day 28 Day 0 0.47 4.47 0.02 10.35 0.619
Navy Bean Rice Bran 9.70 4.76 0.37 251.03 0.161 Day 28 Day 14 0.58 4.47 0.03 12.85 0.723
Navy Bean Control 5.36 5.20 0.17 167.30 0.321 Day 14 Day 0 0.79 2.90 0.08 7.62 0.824
Rice Bran Control 0.34 4.58 0.01 8.00 0.481 Day 28 Day 0 0.35 2.90 0.04 3.38 0.339
Navy Bean Rice Bran 15.98 5.42 0.47 543.04 0.117 Day 28 Day 14 0.44 2.90 0.05 4.31 0.458
Navy Bean Control 4.08 6.33 0.09 191.53 0.455 Day 14 Day 0 0.48 6.93 0.01 26.69 0.706
Rice Bran Control 0.56 5.48 0.02 19.57 0.739 Day 28 Day 0 0.47 6.93 0.01 26.14 0.698
Navy Bean Rice Bran 7.25 6.63 0.14 374.56 0.308 Day 28 Day 14 0.98 6.93 0.02 54.84 0.992
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.75 2.01 0.45 6.88 0.423 Day 14 Day 0 1.06 1.95 0.29 3.93 0.925
Rice Bran Control 1.09 1.94 0.30 4.00 0.897 Day 28 Day 0 0.71 1.99 0.18 2.71 0.611
Navy Bean Rice Bran 1.61 2.05 0.39 6.59 0.511 Day 28 Day 14 0.66 1.98 0.17 2.52 0.546
Navy Bean Control 1.36 1.92 0.38 4.89 0.641 Day 14 Day 0 0.83 1.73 0.28 2.44 0.734
Rice Bran Control 1.07 1.86 0.31 3.61 0.919 Day 28 Day 0 0.89 1.73 0.30 2.63 0.840
Navy Bean Rice Bran 1.27 1.98 0.33 4.85 0.723 Day 28 Day 14 1.08 1.73 0.37 3.17 0.890
Navy Bean Control 2.29 2.16 0.50 10.41 0.283 Day 14 Day 0 1.02 2.42 0.18 5.80 0.979
Rice Bran Control 1.54 2.07 0.37 6.45 0.552 Day 28 Day 0 1.00 2.42 0.18 5.66 0.998
Navy Bean Rice Bran 1.49 2.17 0.32 6.81 0.611 Day 28 Day 14 0.98 2.42 0.17 5.53 0.978
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 1.25 1.75 0.42 3.73 0.692 Day 14 Day 0 0.86 1.63 0.33 2.25 0.760
Rice Bran Control 1.17 1.71 0.41 3.35 0.766 Day 28 Day 0 0.73 1.65 0.27 1.94 0.524
Navy Bean Rice Bran 1.06 1.77 0.35 3.24 0.913 Day 28 Day 14 0.84 1.64 0.32 2.22 0.732
Navy Bean Control 1.24 1.73 0.42 3.62 0.695 Day 14 Day 0 0.85 1.76 0.28 2.59 0.781
Rice Bran Control 1.19 1.66 0.44 3.22 0.726 Day 28 Day 0 0.92 1.75 0.30 2.76 0.878
Navy Bean Rice Bran 1.04 1.73 0.35 3.05 0.946 Day 28 Day 14 1.07 1.75 0.36 3.22 0.899
Navy Bean Control 1.58 1.73 0.54 4.61 0.407 Day 14 Day 0 0.88 1.77 0.29 2.68 0.816
Rice Bran Control 1.37 1.67 0.50 3.77 0.536 Day 28 Day 0 0.85 1.78 0.28 2.63 0.780
Navy Bean Rice Bran 1.15 1.76 0.38 3.48 0.810 Day 28 Day 14 0.97 1.73 0.33 2.84 0.959
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-10 (Multiple Imputation) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-10 (Multiple Imputation) by Time Point






Day 14 0.892 Navy Bean 0.951
Day 28 0.672 Rice Bran 0.936
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-10 (Tobit Regression) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
One-Way Analysis of Variance of Interleukin-10 (Tobit Regression) by Time Point






Day 14 0.892 Navy Bean 0.943
Day 28 0.558 Rice Bran 1.000












Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                                                                                           
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Table 11: Differences in plasma tumor necrosis factor between diet groups (left) and between time points (right) for study 
participants with a history of colorectal cancer (n=23). Only 2 study participants had TNF levels that were below the lowest level 
of detection of the cytokine immunoassay (8.7% at day 0, 0% at day 14, and 0% at day 28). Shown above are analyses of four 
different TNF data sets that each utilized a different approach for managing left-censored data. These approaches are: substitution 
with a fixed value (top), extrapolation using the 5-parametric logistic standard curve equation (second from top), Tobit regression 
(second from bottom), and multiple imputation (bottom). In all four approaches, at day 28, the navy bean group was observed to 







Table 12: Differences in plasma vascular endothelial growth factor between diet groups (left) and between time points (right) for 
study participants with a history of colorectal cancer (n=23). Only a few study participants had VEGF levels that were below the 
lowest level of detection of the cytokine immunoassay (4.3% at day 0, 8.7% at day 14, and 8.7% at day 28). Shown above are 
analyses of four different VEGF data sets that each utilized a different approach for managing left-censored data. These 
approaches are: substitution with a fixed value (top), extrapolation using the 5-parametric logistic standard curve equation 
(second from top), Tobit regression (second from bottom), and multiple imputation (bottom). For the Tobit regression approach, 
at day 28, the navy bean group was observed to have significantly higher plasma VEGF level than the control group. This was 







3.2 Differences in leukocyte telomere length within and between diet groups  
For individuals with a history of colorectal cancer and regardless of the method used for 
telomere length measurement, no significant differences were observed in leukocyte telomere 
length between diet groups or within diet groups over time. However, from day 0 to day 28, the 
rice bran and navy bean groups were both found to have a smaller, although non-significant, 
decrease in multiplex qPCR telomere length when compared to the control group. That is, less 












Figure 4: Graph of relative telomere length for control, navy bean, and rice bran diet groups at day 0 and day 28. Relative 




Table 13: Differences in leukocyte telomere length as measured by multiplex qPCR and IQ-FISH between diet groups (left) and 
between time points (right) for study participants with a history of colorectal cancer. Shown above are analyses of telomere 
length measured by multiplex quantitative polymerase chain reaction (top) and telomere length measured by interphase 
fluorescence in situ hybridization (FISH). Due to variability within the experimental control used for FISH, each batch of 
samples was analyzed separately: batch 1 (second from top; n=6), batch 2 (second from bottom; n=7), and batch 3 (bottom; n=8). 
No significant differences were observed between diet groups or time point for telomere length measured by multiplex qPCR and 









Table 14: Differences in leukocyte telomere length measured by singleplex qPCR diet groups (left) and between time points 
(right) for study participants with a history of colorectal cancer. Shown above are data analyses from plate 1 (top), plate 2 
(middle), and both plates combined (bottom). The experimental plates were normalized to a control cell line. However, given the 
variability observed within the control telomere length measured by FISH, the singleplex qPCR plates were analyzed separately 
















Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 0.406 1.875 0.098 1.684 0.186 Day 14 Day 0 1.11 1.53 0.42 2.91 0.820
Rice Bran Control 0.676 1.875 0.163 2.804 0.549 Day 28 Day 0 0.93 1.53 0.35 2.46 0.877
Navy Bean Rice Bran 0.601 1.875 0.145 2.490 0.438 Day 28 Day 14 0.85 1.53 0.32 2.23 0.704
Navy Bean Control 0.576 1.658 0.184 1.807 0.304 Day 14 Day 0 1.57 1.81 0.41 6.00 0.469
Rice Bran Control 0.904 1.658 0.288 2.835 0.846 Day 28 Day 0 1.29 1.81 0.34 4.95 0.675
Navy Bean Rice Bran 0.637 1.658 0.203 2.000 0.396 Day 28 Day 14 0.83 1.81 0.22 3.16 0.754
Navy Bean Control 0.563 1.766 0.155 2.037 0.338 Day 14 Day 0 1.48 1.94 0.33 6.60 0.570
Rice Bran Control 1.041 1.766 0.288 3.768 0.945 Day 28 Day 0 1.44 1.94 0.32 6.43 0.597
Navy Bean Rice Bran 0.540 1.766 0.149 1.957 0.307 Day 28 Day 14 0.97 1.94 0.22 4.35 0.969
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 2.87 2.11 0.49 16.82 0.201 Day 14 Day 0 1.58 1.80 0.44 5.71 0.451
Rice Bran Control 1.16 1.92 0.25 5.44 0.825 Day 28 Day 0 1.46 1.80 0.40 5.27 0.533
Navy Bean Rice Bran 2.47 2.26 0.36 17.01 0.304 Day 28 Day 14 0.92 1.80 0.26 3.33 0.893
Navy Bean Control 1.76 1.90 0.38 8.05 0.408 Day 14 Day 0 0.97 1.99 0.11 8.72 0.968
Rice Bran Control 1.53 1.75 0.41 5.76 0.474 Day 28 Day 0 1.42 1.99 0.16 12.78 0.645
Navy Bean Rice Bran 1.15 2.02 0.22 6.05 0.847 Day 28 Day 14 1.47 1.99 0.16 13.17 0.618
Navy Bean Control 2.80 1.96 0.57 13.74 0.171 Day 14 Day 0 2.08 1.68 0.59 7.42 0.207
Rice Bran Control 1.47 1.80 0.37 5.90 0.533 Day 28 Day 0 1.85 1.68 0.52 6.58 0.282
Navy Bean Rice Bran 1.90 2.08 0.33 10.81 0.410 Day 28 Day 14 0.89 1.68 0.25 3.16 0.824
Time Point Parameter





Type III          
p-value
Diet Parameter





Type III          
p-value
Navy Bean Control 0.92 1.62 0.33 2.52 0.857 Day 14 Day 0 1.35 1.46 0.62 2.94 0.434
Rice Bran Control 0.93 1.59 0.36 2.46 0.886 Day 28 Day 0 1.20 1.46 0.55 2.61 0.638
Navy Bean Rice Bran 0.98 1.66 0.34 2.85 0.968 Day 28 Day 14 0.89 1.46 0.41 1.93 0.754
Navy Bean Control 0.91 1.46 0.41 2.00 0.798 Day 14 Day 0 1.34 1.71 0.43 4.18 0.597
Rice Bran Control 1.19 1.44 0.56 2.53 0.644 Day 28 Day 0 1.34 1.71 0.43 4.18 0.597
Navy Bean Rice Bran 0.76 1.49 0.33 1.77 0.510 Day 28 Day 14 1.00 1.71 0.32 3.13 0.999
Navy Bean Control 1.02 1.54 0.41 2.53 0.962 Day 14 Day 0 1.71 1.50 0.73 4.02 0.203
Rice Bran Control 1.25 1.51 0.52 2.98 0.597 Day 28 Day 0 1.60 1.50 0.68 3.76 0.263






























Comparison groups 95% Confidence Limits
Day 0







Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                      
One-Way Analysis of Variance of Singleplex qPCR Telomere Length (Plate 1) by Diet Group
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One-Way Analysis of Variance of Singleplex qPCR Telomere Length (Plate 2) by Diet Group
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Way Analysis of Variance of Singleplex qPCR Telomere Length (Plate 2) by Time Point
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                      
One-Way Analysis of Variance of Singleplex qPCR Telomere Length (Plates 1 & 2) by Diet Group
Parameter Estimates for Study Participants with a History of Colorectal Cancer:                                                                                      One-




3.3 Differences in lipid levels within and between diet groups 
3.3.1 Study participants without a history of colorectal cancer 
 Within each respective diet group, no significant differences were observed between 
serum levels of total cholesterol, LDL, HDL, and triglycerides measured at day 0, day 14, and 
day 28 for study participants who did not have a history of colorectal cancer.  
 In regards to inter-group comparison of lipid levels, the only significant difference 
between diets was found at day 28, where the navy bean diet group possessed a significantly 
higher level of HDL compared to the rice bran group (µNB-µRB=56.75 mg/dL; 95% CI [37.89, 
75.61]; p<0.0001). This difference was not significant at day 0 or day 14 of the study. In 
comparison to the control group, no significant differences were found with either the rice bran 






















Table 15: Differences in serum lipids between diet groups (left) and between time points (right) for study participants without a 
history of colorectal cancer. Variables shown above: total cholesterol (top), low-density lipoprotein (LDL; second from top), 
high-density lipoprotein (HDL; second from bottom), and triglycerides (bottom). At day 28, the navy bean group (n=4) was 
observed to have significantly higher levels of HDL than the rice bran group (n-4). Otherwise, no significant differences were 








3.3.2 Study participants with a history of colorectal cancer 
 Within each respective diet group, no significant changes were found between serum 
levels of total cholesterol, LDL, HDL, and triglycerides measured at day 0, day 14, and day 28 
for study participants with a history of colorectal cancer. Significant differences were observed 
between the diet groups.  
For the colorectal cancer cohort, initial total cholesterol for individuals within the rice 
bran dietary group was significantly greater than individuals assigned to a control diet (µRB– µCtrl 
=42.00 mg/dL; 95% CI [1.38, 82.62]; p=0.043). This difference was also present at day 14 of the 
study (µRB– µCtrl =45.92 mg/dL; 95% CI [7.74, 84.10];  p=0.020) but was no longer observed to 
be significant at day 28 (µRB– µCtrl =38.01 mg/dL; 95% CI [-0.07, 76.09];  p=0.0504). This same 
group of individuals was also found to have a significantly higher LDL level than the control 
group at all time points of the study (Day 0: µRB– µCtrl=37.29 mg/dL; 95% CI [3.72, 70.86]; 
p=0.031; Day 14: µRB– µCtrl=42.07 mg/dL; 95% CI [11.07, 73.06]; p=0.010; Day 28: µRB– 
µCtrl=35.00 mg/dL; 95% CI [1.50, 68.50]; p=0.041). No significant differences between the navy 
bean diet group and the control diet group were discovered in total cholesterol, LDL, HDL, and 
triglycerides. Similarly, no significant difference was observed between the rice bran and control 


















Table 16: Differences in serum levels of total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides 
between diet groups (left) and between time points (right) for study participants with a history of colorectal cancer. Variables 
shown above: total cholesterol (top), low-density lipoprotein (LDL; second from top), high-density lipoprotein (HDL; second 
from bottom), and triglycerides (bottom). Total cholesterol of the rice bran group (n=9) was observed to be significantly greater 
than the control group (n=10) at day 0 and day 14. Similarly, LDL of the rice bran group was observed to significantly greater 







3.4 Differences in nutrient intake within diet groups 
3.4.1 Study participants without a history of colorectal cancer 
 Within diet groups, individuals without a history of colorectal cancer were only found to 
have a few significant changes in nutrient intake over the course of the study. For the rice bran 
diet, vitamin A was found to be significantly decreased at day 28 compared to day 0 
(RoGM=0.44; 95% CI=[0.29, 0.67]; p=0.002). A similar decrease was found in vitamin A intake 
from day 14 to day 28 (RoGM=0.64; 95% CI=[0.42, 0.97]; p=0.038). Within the navy bean diet 
group, protein intake was found to have significantly decreased at day 28 compared to day 0 
(µd28-µd0=-23.80 g; 95% CI=[-44.68, -2.91]; p=0.031). 
 
3.4.2 Study participants with a history of colorectal cancer 
 When compared to their initial intake, individuals with a history of colorectal cancer who 
consumed a rice bran or navy bean supplemented diet were observed to have significant 
increases in several vitamins and minerals.  
By day 14, the rice bran group was found to have significantly greater levels of intake of 
vitamin A (RoGM=1.72; 95% CI=[1.03, 2.88]; p=0.040), β-carotene (RoGM=3.25; 95% 
CI=[1.39, 8.12]; p=0.014), vitamin C (RoGM=1.75; 95% CI=[1.00, 3.06]; p=0.049), α-
Tocopherol (RoGM=1.54 95% CI=[1.19, 1.99]; p=0.002), vitamin B1 (RoGM=1.82; 95% 
CI=[1.50, 2.20]; p=<0.0001), vitamin B3 (µd14– µd0 =9.32 µg; 95% CI=[4.28, 14.36]; p=0.001), 
vitamin B6 (RoGM=1.07; 95% CI=[1.74, 2.27]; p=<0.0001), potassium (RoGM=1.29; 95% 
CI=[1.09, 1.52]; p=0.004), and fiber (RoGM=1.36; 95% CI=[1.06, 1.73]; p=0.017) when 
compared to the start of the study. Similar differences in intake for the rice bran group were 




carotene (RoGM=3.68; 95% CI=[1.47, 9.18]; p=0.007), vitamin C (RoGM=1.98; 95% CI=[1.13, 
3.45]; p=0.019), α-Tocopherol (RoGM=1.63; 95% CI=[1.26, 2.10]; p=0.001), vitamin B1 
(RoGM=1.90; 95% CI=[1.56, 2.30]; p=<0.0001), vitamin B3 (µd28– µd0 =8.19 µg; 95% CI=[3.15, 
13.22]; p=0.003), vitamin B6 (RoGM=2.05; 95% CI=[1.79, 2.34]; p=<0.0001), potassium 
(RoGM=1.41; 95% CI=[1.19, 1.66]; p=0.0003), and fiber (RoGM=1.41; 95% CI=[1.10, 1.80]; 
p=0.008). 
For the navy bean diet group, significant differences were found between day 14 and day 
0 for vitamin A (RoGM=1.87; 95% CI=[1.13, 3.09]; p=0.016), β-carotene (RoGM=3.27; 95% 
CI=[1.35, 7.87]; p=0.010), zinc (RoGM=1.57; 95% CI=[1.11, 2.22]; p=0.013), potassium 
(RoGM=1.66; 95% CI=[1.35, 2.05]; p=<0.0001), and fiber (RoGM=1.59; 95% CI=[1.18, 2.13]; 
p=0.003). The same variables were significantly greater at day 28 compared to day 0: vitamin A 
(RoGM=2.18; 95% CI=[1.32, 3.60]; p=0.040), β-carotene ((RoGM=3.81; 95% CI=[1.58, 9.19]; 
p=0.004), zinc (RoGM=1.58; 95% CI=[1.12, 2.23]; p=0.012), potassium (RoGM=1.79; 95% 
CI=[1.45, 2.20]; p=<0.0001), and fiber (RoGM=1.81; 95% CI=[1.35, 2.43]; p=0.0003). 
Additionally, significant increases in the intake of vitamin B9 (RoGM=1.44; 95% CI=[1.00, 
2.06]; p=0.0499) and linolenic acid (RoGM=1.64; 95% CI=[1.05, 2.54]; p=0.030) was found 
between day 28 and day 0 for the navy bean diet.  
Within the control diet, the only variable found to have a significant change from day 0 
was saturated fat. At day 14, saturated fat intake was significantly greater than at day 0 
(RoGM=1.27; 95% CI=[1.00, 1.62]; p=0.0498). However, at day 28, no significant difference in 






3.5 Differences in nutrient intake between diet groups 
3.5.1 Study participants without a history of colorectal cancer 
 Within individuals without a history of colorectal cancer, only a few significant 
differences were found between diet groups. At day 0, vitamin A intake was observed to be 
significantly higher in the rice bran group compared to the control group (RoGM=2.05; 95% 
CI=[1.45, 2.90]; p=0.001). A similar relationship was found in the difference of vitamin A intake 
at day 0 between the navy bean and rice bran groups (RoGM=0.49; 95% CI=[0.36, 0.68]; 
p=0.001). However, no significant relationship in vitamin A intake was found between any 
group at day 14 or day 28.  
In regards to the rice bran and control groups, the only significant relationships other than 
vitamin A intake were found at day 14 within calcium (RoGM=1.33; 95% CI=[1.02, 1.73]; 
p=0.036) and fiber (RoGM=1.48, 95% CI=[1.97, 2.04]; p=0.023) intakes.  
  Lastly, at day 0, iron intake was observed to be significantly lower in the navy bean 
group compared to the control (RoGM=0.70; 95% CI=[0.54, 0.90]; p=0.011) and rice bran 
(RoGM=0.69; 95% CI=[0.54, 0.87]; p=0.006) groups.  
 
3.5.2 Study participants with a history of colorectal cancer 
 At day 0, the only significant differences in nutrient intake between diet groups existed 
between the navy bean and control diets. Within the navy bean group, intakes of vitamin D 
(RoGM=0.25; 95% CI=[0.08, 0.78]; p=0.019), vitamin B2 (µNB– µCtrl =-0.46 µg; 95% CI=[-0.87, 
-0.05]; p=0.030), and potassium (RoGM=0.72; 95% CI=[0.55, 0.96]; p=0.027) were each 




 By day 14, several more significant differences were observed between the navy bean 
and control group. Along with the sustained differences in vitamin D (RoGM=0.57; 95% 
CI=[0.34, 0.94]; p=0.030) and vitamin B2 (µNB– µCtrl =-0.41 µg; 95% CI=[-0.65, -0.18]; 
p=0.001) at day 14, previously unseen significant differences were found between the navy bean 
and control group in respect to intake of vitamin B12 (RoGM=0.58; 95% CI=[0.39, 0.87]; 
p=0.011), fat (µNB-µCtrl=-18.77 µg; 95% CI=[-37.10, -0.44]; p=0.045), and linolenic acid 
(RoGM=1.56; 95% CI=[1.08, 2.25]; p=0.019). Additionally, potassium intake at day 14 within 
the navy bean group was observed to be significantly higher than in the control group 
(RoGM=1.19; 95% CI=[1.01, 1.40]; p=0.036); this is an opposite relationship as that found at 
day 0.  
 At day 28, differences between the respective intakes of vitamin D, vitamin B2, vitamin 
B12, fat, and linolenic acid within the navy bean and control diet were no longer significant. The 
only significant relationships at day 28 were found within intake of vitamin B2 (µNB– µCtrl =-0.34 
µg; 95% CI=[-0.61, -0.08]; p=0.013), potassium (RoGM=1.22; 95% CI=[1.01, 1.48]; p=0.041), 
and fiber (RoGM=1.41; 95% CI=[1.13, 1.72]; p=0.003).  
Between the rice bran and control diets, at day 14, significantly greater levels of intake 
were observed in the rice bran group for vitamin B1 (RoGM=1.69; 95% CI=[1.30, 2.19]; 
p=0.0003), vitamin B3 (µRB– µCtrl =10.17 µg; 95% CI=[5.43, 14.92]; p=0.0002), vitamin B6 
(RoGM=1.77; 95% CI=[1.47, 2.13]; p=<0.0001), and fiber (RoGM=1.22; 95% CI=[1.01, 1.48]; 
p=0.041). Similar relationships were found at day 28: vitamin B1 (RoGM=1.37; 95% CI=[1.10, 
1.70]; p=0.007), vitamin B3 (µRB– µCtrl =7.62 µg; 95% CI=[2.52, 12.72]; p=0.005), vitamin B6 





 Comparison of the navy bean and rice bran groups at day 14 revealed significantly less 
intake within the navy bean group of α-Tocopherol (RoGM=0.70; 95% CI=[0.51, 0.98]; 
p=0.036), vitamin B1 (RoGM=0.50; 95% CI=[0.39, 0.65]; p=<0.0001), vitamin B2 (µNB– µRB =-
0.29 µg; 95% CI=[-0.53, -0.05]; p=0.022), vitamin B3 (µNB– µRB =-12.03 µg; 95% CI=[-16.78, -
7.29]; p=<0.0001), vitamin B6 (RoGM=0.49; 95% CI=[0.41, 0.59]; p=<0.0001), vitamin B12 
(RoGM=0.64; 95% CI=[0.42, 0.97]; p=0.036), oleic acid (RoGM=0.69; 95% CI=[0.49, 0.96]; 
p=0.031), linoleic acid (RoGM=0.61; 95% CI=[0.40, 0.93]; p=0.024), and linolenic acid 
(RoGM=0.56; 95% CI=[0.39, 0.80]; p=0.003). However, at day 28, the only significant 
differences between the navy bean and rice bran diets were found in vitamin B1 (RoGM=0.59; 
95% CI=[0.47, 0.73]; p=<0.0001), vitamin B3 (µNB– µRB =-9.00 µg; 95% CI=[-14.10, -3.90]; 
p=0.001), and vitamin B6 (RoGM=0.52; 95% CI=[0.41, 0.66]; p=<0.0001). The significant 
differences between the navy bean and rice bran diets that were found in α-Tocopherol, vitamin 



















Table 17: Differences in vitamin A, vitamin C, zinc, and calcium intake between diet groups (left) and between time points 
(right) for study participants without a history of colorectal cancer. Variables shown above: vitamin A intake (top), vitamin C 
intake (second from top), zinc intake (second from bottom), and calcium intake (bottom). At day 0, vitamin A intake within the 
rice bran treatment group (n=4) was significantly greater than both the navy bean (n=4) and control (n=3) treatment groups. Over 
the duration of the study, vitamin A intake within the rice bran group decreased by day 28 was significantly less than at day 0 and 
day 14. Additionally, at day 14, calcium intake within the rice bran group significantly greater than the control group. Otherwise, 







Table 18: Differences in potassium, sodium, and iron intake between diet groups (left) and between time points (right) for study 
participants without a history of colorectal cancer. Variables shown above: potassium intake (top), sodium intake (middle), and 
iron intake (bottom). At day 0, iron intake within the navy bean treatment group (n=4) was significantly less than both the rice 
bran (n=4) and control (n=3) treatment groups. Otherwise, no significant differences were observed in the displayed variables 


















Table 19: Differences in calorie, protein, and carbohydrate intake between diet groups (left) and between time points (right) for 
study participants without a history of colorectal cancer. Variables shown above: calorie intake (top), protein intake (middle), and 
carbohydrate intake (bottom). Within the navy bean treatment group (n=4), protein intake was significantly lower at day 28 than 



















Table 20: Differences in fat, saturated fat, and fiber intake between diet groups (left) and between time points (right) for study 
participants without a history of colorectal cancer. Variables shown above: total fat intake (top), saturated fat intake (middle), and 
fiber intake (bottom). At day 14, fiber intake within the rice bran treatment group (n=4) was significantly greater than the control 
group (n=3). Otherwise, no significant differences were observed in the displayed variables between treatment groups or time 
points. A natural logarithm was performed on all data shown above, and a ratio of geometric means was obtained after back 
transformation. Confidence intervals and standard errors displayed are for the ratio of the respective comparison group means 







Table 21: Differences in vitamin A, β-Carotene, and vitamin C intake between diet groups (left) and between time points (right) 
for study participants with a history of colorectal cancer (n=29). Variables shown above: vitamin A intake (top), β-carotene 
intake (middle), and vitamin C intake (bottom). Within both the navy bean (n=10) and rice bran (n=9) groups, vitamin A and β-
carotene intake were both significantly greater at day 28 and day 14 than at day 0. Additionally, within the rice bran group, 






Table 22: Differences in vitamin D, vitamin E, and α-Tocopherol intake between diet groups (left) and between time points 
(right) for study participants with a history of colorectal cancer (n=29). Variables shown above: vitamin D intake (top), vitamin A 
intake (middle), and α-Tocopherol intake (bottom). At day 0 and day 14, the navy bean group (n=10) was observed to have a 
significantly lower intake of vitamin D than the control group (n=10). At day 28 and day 14, the rice bran group (n=9) had 















Table 23: Differences in intake of vitamin B1 (thiamin), vitamin B2 (riboflavin), and vitamin B3 (niacin) between diet groups 
(left) and between time points (right) for study participants with a history of colorectal cancer (n=29). Variables shown above: 
vitamin B1 intake (top), vitamin B2 intake (middle), and vitamin B3 intake (bottom). At day 14 and day 28, the rice bran group 
(n=9) was observed to have a significantly greater intake of vitamin B1 than both the control (n=10) and navy bean (n=10) 
groups. Accordingly, vitamin B1 intake for the rice bran group was significantly greater at day 28 and day 14 compared to day 0. 
Additionally, at day 28, the navy bean group had a significantly lower intake of vitamin B1 than the control group. In regards to 
vitamin B2, at all time points, the navy bean group had a significantly lower intake than the control group. Finally, for vitamin 
B3, at day 14 and day 28, the rice bran group was observed to have a significantly larger intake than the control and navy bean 







Table 24: Differences in intake of vitamin B6 (pyridoxine), vitamin B9 (folate), and vitamin B12 (cobalamin) between diet 
groups (left) and between time points (right) for study participants with a history of colorectal cancer (n=29). Variables shown 
above: vitamin B6 intake (top), vitamin B9 intake (middle), and vitamin B12 intake (bottom). In regards to vitamin B6 intake, at 
day 14 and day 28, the rice bran group (n=9) was observed to have a significantly greater intake than both the control (n=10) and 
navy bean (n=10) groups. Accordingly, vitamin B6 intake for the rice bran group at day 28 and day 14 was significantly greater 
compared to day 0. For vitamin B12 intake, at day 14, the navy bean group was observed to have a significantly lower intake than 
both the control and rice bran groups. Otherwise, no significant differences were observed in the displayed variables between 













Table 25: Differences in intake of zinc, calcium, potassium, and sodium between diet groups (left) and between time points 
(right) for study participants with a history of colorectal cancer (n=29). Variables shown above: zinc intake (top), calcium intake 
(second from top), potassium intake (second from bottom), and sodium intake (bottom). In regards to zinc intake, at day 14 and 
day 28, the navy bean group (n=10) was observed to have a significantly greater intake than at day 0, and no significant 
differences were observed between diet groups. For potassium intake, the navy bean group was observed to have a significantly 
greater intake than the control group (n=10) at all time points. Additionally, both the navy bean and rice bran groups had 
significantly greater potassium intake at day 14 and day 28 compared to day 0.  Accordingly, vitamin B6 intake for the rice bran 
group at day 28 and day 14 was significantly greater compared to day 0. Otherwise, no significant differences were observed in 






Table 26: Differences in intake of iron, magnesium, and selenium between diet groups (left) and between time points (right) for 
study participants with a history of colorectal cancer (n=29). Variables shown above: iron intake (top), magnesium intake 
(middle), and selenium intake (bottom). In regards to iron intake, at day 14 and day 28, the rice bran group (n=9) was observed to 
have a significantly greater intake than the control (n=10) and navy bean (n=10) groups, and within the rice bran group, iron 
intake was significantly greater at day 28 and day 14 than at day 0. The navy bean group was also observed to have a 
significantly greater potassium intake at day 28 and day 14 than at day 0. For magnesium, at day 14 and day 28, the rice bran 
group had significantly greater intake than both the control and navy bean groups. At day 14 and day 28, both the navy bean and 
rice bran groups had significantly greater potassium intake compared to their respective intake at day 0. Finally, at day 14, the 
navy bean group was observed to have a significantly lower selenium intake than both the control and rice bran groups. 













Table 27: Differences in calorie, protein, carbohydrate, and fat intake between diet groups (left) and between time points (right) 
for study participants with a history of colorectal cancer (n=29). Variables shown above: calorie intake (top), protein intake 
(second from top), carbohydrate intake (second from bottom), and fat intake (bottom). The only significant difference observed 
within these variables was in regards to the lower fat intake of the navy bean group (n=10) compared to the control group (n=10) 

















Table 28: Differences in saturated fat, oleic acid, linoleic acid, and linolenic acid intake between diet groups (left) and between 
time points (right) for study participants with a history of colorectal cancer (n=29). Variables shown above: saturated fat intake 
(top), oleic acid intake (second from top), linoleic acid intake (second from bottom), and linolenic acid intake (bottom). At day 
14, the rice bran group (n=9) was observed to have a significantly greater intake of oleic acid, linoleic acid, and linolenic acid 
compared to the navy bean group (n=10). Similarly, the rice bran group had a significantly greater linolenic acid intake compared 
to control group (n=10) at day 14. However, no significant differences in fatty acid intake were observed between groups at day 0 
or day 28. Within groups, the navy bean group was found to have a significantly greater intake of linolenic acid at day 28 
compared to day 0, and the control group was found to have a significantly greater intake of saturated fat at day 14 compared to 







Table 29: Differences in fiber intake between diet groups (left) and between time points (right) for study participants with a 
history of colorectal cancer (n=29). The rice bran (n=9) and navy bean (n=10) groups both displayed a significantly greater fiber 
intake at day 28 and day 14 compared to day 0. Additionally, at day 28, these groups were both found to have significantly 
greater fiber intake compared to the control group (n=10), and at day 14, the fiber intake in the rice bran group was also 























3.6 Differences in telomere length and cytokine concentrations between sexes 
 Relative telomere length as measured by multiplex qPCR was found to be significantly 
longer in females than males at day 0 (µf-µm=0.34; 95% CI=[0.06, 0.61]; p=0.020) but not at day 
28 (µf-µm=0.27; 95% CI=[0.0.1, 0.53]; p=0.185). No significant differences were observed 
between sexes in telomere length as measured by singleplex qPCR or IQ-FISH.   
 Analysis of plasma cytokine concentrations from the substitution data set indicated that at 
day 0, females had significantly lower levels of IL-4 (RoGM=0.29; 95% CI=[0.10, 0.81]; 
p=0.020), IL-6 (RoGM=0.43; 95% CI=[0.23, 0.82]; p=0.013), and IL-10 (RoGM=0.36; 95% 
CI=[0.14, 0.90]; p=0.031) when compared to males. These differences were also significant at 
day 14: IL-4 (RoGM=0.34; 95% CI=[0.12, 0.92]; p=0.035), IL-6 (RoGM=0.38; 95% CI=[0.20, 
0.72]; p=0.004), and IL-10 (RoGM=0.32; 95% CI=[0.13, 0.75]; p=0.011). Additionally, at day 
14, females were found to have significantly lower levels of IL-8 (RoGM=0.46; 95% CI=[0.29, 
0.74]; p=0.003). No significant difference was observed between sexes for any cytokines at day 
28.  
 Within the extrapolated data set, at day 0, females were only found to have significantly 
lower levels of IL-10 (RoGM=0.06; 95% CI=[0.01, 0.58]; p=0.018) compared to males. At day 
14, IL-10 was still significantly lower in females than in males (RoGM=0.06; 95% CI=[0.005, 
0.83]; p=0.037). Additionally, at day 14, females had significantly lower levels of IL-4 
(RoGM=0.05; 95% CI=[0.003, 0.98]; p=0.049), IL-6 (RoGM=0.12; 95% CI=[0.02, 0.65]; 
p=0.017), and IL-8 (RoGM=0.50; 95% CI=[0.34, 0.75]; p=0.002) compared to males. At day 28, 
similar to the substitution data set, no significant differences in plasma cytokine concentrations 





Table 30: Differences in leukocyte telomere length between sexes for study participants with a history of colorectal cancer 
(n=27). Telomere length measured by multiplex qPCR is the most reliable estimate in this report. At day 0, females (n=15) had 
significantly longer telomeres than males (n=12). However, no significant difference in telomere length was found between sexes 










































Table 31: Differences in plasma cytokine concentrations between sexes for study participants with a history of colorectal cancer 
(n=29). At day 0, when using the substitution method for handling censored data, females had lower IL-4, IL-6, and IL-10 
concentrations. When using the extrapolation method, females did not have significantly lower IL-4 concentrations at day 0 but 
did have significantly lower IL-6 and IL-10 concentrations at day 0. At day 28, no significant differences in cytokine 















3.7 Differences in lipid levels between sexes 
 Females were found to have significantly higher levels of HDL and significantly lower 
levels of triglycerides at all three time points. No significant differences were found between 
females and males for total cholesterol or LDL.  
On average, females had triglyceride levels approximately 40% lower than males: day 0 
(RoGM=0.60; 95% CI=[0.41, 0.88]; p=0.010), day 14 (RoGM=0.65; 95% CI=[0.44, 0.96]; 
p=0.033), and day 28 (RoGM=0.61; 95% CI=[0.41, 0.91]; p=0.016). In regards to HDL, females 
had ~34% higher serum HDL levels compared to males: day 0 (µf-µm=18.59 mg/dL; 95% 
CI=[9.44, 27.75]; p=0.0003), day 14 (µf-µm=19.20 mg/dL; 95% CI=[10.24, 28.16]; p=0.0002), 









Table 32: Differences in age, weight, BMI, and cholesterol between sexes for study participants with a history of colorectal 
cancer (n=29). Compared to males (n=12), females (n=17) had significantly higher serum HDL and significantly lower serum 
triglycerides at all time points. 
 
 
Table 33: Difference in serum triglyceride levels between sexes for study participants with a history of colorectal cancer (n=29). 
Compared to males (n=12), females (n=17) had significantly lower serum triglycerides at all time points. Triglyceride data was 
not distributed normally, and a natural logarithm transformation was performed prior to analysis. A back transformation was 
















3.8 Differences in nutrient intake between sexes 
Females and males were found to have marked differences in intake of several different 
vitamins, minerals, and macronutrients. At both day 0, females were found to have significantly 
lower levels of intake of vitamin B2 (µf-µm=-0.62; 95% CI=[-1.16, -0.08]; p=0.026), zinc 
(RoGM=0.623; 95% CI=[0.557, 0.698]; p=0.008), sodium (µf-µm=-650.1 mg; 95% CI=[-1292.1, 
-8.2]; p=0.047), selenium (µf-µm=-40.7 mg; 95% CI=[-68.0, -13.3]; p=0.028), carbohydrates 
(RoGM=0.77; 95% CI=[0.61, 0.98]; p=0.036), protein (µf-µm=-28.1 g; 95% CI=[-43.2, -12.9]; 
p=0.001), calories (µf-µm=-589.4; 95% CI=[-986.3, -192.5]; p=0.005), fat (µf-µm=-22.3 g; 95% 
CI=[-44.4, -0.2]; p=0.048), saturated fat (RoGM=0.76; 95% CI=[0.59, 0.98]; p=0.038), and 
linoleic acid (RoGM=0.55; 95% CI=[0.31, 0.99]; p=0.047). These same nutrients were also 
significantly were also consumed less by females at day 28: vitamin B2 (µf-µm=-0.51; 95% CI=[-
0.95, -0.07]; p=0.024), zinc (RoGM=0.803; 95% CI=[0.79, 0.82]; p=0.022), sodium (µf-µm=-
696.8 mg; 95% CI=[-1140.4, -253.2]; p=0.003), selenium (µf-µm=-20.9 mg; 95% CI=[-39.5, -
2.4]; p=0.028), carbohydrates (RoGM=0.82; 95% CI=[0.70, 0.96]; p=0.017), protein (µf-µm=-
17.4 g; 95% CI=[-30.0, -4.8]; p=0.009), calories (µf-µm=-523.8; 95% CI=[-818.3, -229.3]; 
p=0.001), fat (µf-µm=-20.9 g; 95% CI=[-37.8, -4.1]; p=0.017), saturated fat (RoGM=0.76; 95% 
CI=[0.59, 0.98]; p=0.038), and linoleic acid (RoGM=0.71; 95% CI=[0.51, 0.98]; p=0.038). 
Additionally, at day 28, iron intake in females was significantly less than in males (RoGM=0.77; 
95% CI=[0.63, 0.95]; p=0.017). No significant differences between females and males were 







Table 34: Differences in vitamin intake between sexes for study participants with a history of colorectal cancer (n=29). No 
significant differences between males and females were found in intake of the vitamins listed above. All displayed variables were 
not distributed normally, and a natural logarithm transformation was performed prior to analysis. A back transformation was 




Table 35: Differences in vitamin B2 and vitamin B3 intake between sexes for study participants with a history of colorectal 
cancer (n=29). At day 0 and day 28, females (n=17) were found to have significantly lower intake of vitamin B2 than males. No 










Table 36: Differences in intake of minerals, macronutrients, fatty acids, and fiber between sexes for study participants with a 
history of colorectal cancer (n=29). At day 0 and day 28, females had significantly lower intake of zinc, carbohydrates, saturated 
fat, and linoleic acid. Additionally, at day 28, females had significantly lower intake of iron compared to males. All displayed 
variables were not distributed normally, and a natural logarithm transformation was performed prior to analysis. A back 
























Table 37: Differences in intake of sodium, selenium, calories, protein, and total fat between sexes for study participants with a 
history of colorectal cancer (n=29). At day 0 and day 28, females had significantly lower intake of sodium, selenium, calories, 






















3.9 Linear repeated measures correlations  
 Linear associations between study variables were evaluated using a repeated measure 
correlation model with adjustment for the influences of age, sex, and total energy intake. Overall, 
significant correlations observed in the present study were consistent with prior studies.  
 BMI was positively correlated with triglyceride level (r=0.3439; p=0.0107) and saturated 
fat intake (r=0.3700; p=0.0023) and negatively correlated with β-Carotene intake (r=-0.2965; 
p=0.0124) and vitamin C intake (r=-0.3086; p=0.0095).  
In regards to lipid profile, total serum cholesterol was positively correlated with saturated 
fat intake (r=0.2564; p=0.0433) and negatively correlated with β-Carotene intake (r=-0.3524; 
p=0.0060). Similarly, LDL cholesterol was negatively correlated with β-Carotene intake         
(r=-0.2746; p=0.0340). HDL cholesterol was positively correlated with saturated fat intake 
(r=0.3775; p=0.0120) and linolenic acid intake (r=0.4969; p=0.0014). Triglyceride level was 
positively correlated with selenium intake (r=0.2932; p=0.0291) and negatively correlated with 
β-Carotene intake (r=-0.2394; p=0.0406), fiber intake (r=-0.3792; p=0.0018), and leukocyte 
telomere length (r=-0.2992; p=0.0499). 
Several plasma cytokines were significantly correlated with various dietary factors. 
Plasma IL-2 concentration was negatively correlated with α-Tocopherol intake for both the 
substitution (r=-0.3773; p=0.0151) and extrapolation (r=-0.3731; p=0.0177) data sets. Similarly, 
plasma IL-4 concentration was negatively correlated with α-Tocopherol intake for both the 
substitution (r=-0.4381; p=0.0042) and extrapolation (r=-0.4111; p=0.0087) data sets. Plasma IL-
8 concentration was negatively correlated with vitamin B3 intake for both the substitution (r=-
0.2889; p=0.0365) and extrapolation (r=-0.2933; p=0.0478) data sets. Plasma VEGF 




(r=0.2928; p=0.0322) and extrapolation (r=0.3071; p=0.0229) data sets. No significant 
correlations were found for IL-6, IL-10, or TNF.  
As expected, telomere length was significantly correlated with age after adjusting for sex 
(r=-0.6162; p<0.0001). Additionally, telomere length was negatively correlated with triglyceride 











Figure 5: Graphs showing significant correlations for lipid profile for participants with a history of colorectal cancer. Each graph 
shows data points at all three time points. The coefficient of correlation was determined by a repeat measures statistical method 
using an unstructured correlation matrix. The graphs are meant for display purposes and do not directly represent the coefficient 






Figure 6: Figure 7: Graphs showing significant correlations for telomere length for participants with a history of colorectal 
cancer. Each graph shows data points at all three time points. The coefficient of correlation was determined by a repeat measures 
statistical method using an unstructured correlation matrix. The graphs are meant for display purposes and do not directly 











Figure 8: Graphs showing significant correlations for telomere length for participants with a history of colorectal cancer. Each 
graph shows data points at all three time points. The coefficient of correlation was determined by a repeat measures statistical 
method using an unstructured correlation matrix. The graphs are meant for display purposes and do not directly represent the 




Table 38: Linear correlations between weight, BMI, serum lipids, and leukocyte telomere length. Correlation analysis was 
performed on repeated measures of each variable, and age and sex were used as covariates. Telomere length was inversely 




Table 39: Linear correlations for IL-2, IL-4, and IL-6 concentrations with weight, BMI, serum lipids, and leukocyte telomere 







Table 40: Linear correlations for IL-8, IL-10, TNF, and VEGF concentrations with weight, BMI, serum lipids, and leukocyte 































Table 41: Linear correlations vitamin intake with weight, BMI, serum lipids, and leukocyte telomere length. Correlation analysis 
was performed on repeated measures of each variable, and age and sex were used as covariates. Additionally, all dietary intakes 
were adjusted for total calorie intake. β-Carotene was significantly inversely correlated with weight, BMI, total cholesterol, LDL, 




























Table 42: Linear correlations for B vitamin intake with weight, BMI, serum lipids, and leukocyte telomere length. Correlation 
analysis was performed on repeated measures of each variable, and age and sex were used as covariates. Additionally, all dietary 





























Table 43: Linear correlations for mineral intake with weight, BMI, serum lipids, and leukocyte telomere length. Correlation 
analysis was performed on repeated measures of each variable, and age and sex were used as covariates. Additionally, all dietary 




























Table 44: Linear correlations for total protein, carbohydrate, fat, saturated fat, oleic acid, linoleic acid, and linolenic acid intake 
with weight, BMI, serum lipids, and leukocyte telomere length. Correlation analysis was performed on repeated measures of each 
variable, and age and sex were used as covariates. Additionally, all dietary intakes were adjusted for total calorie intake. 
Saturated fat intake was positively correlated with weight, BMI, total cholesterol, and HDL and was negatively correlated with 
telomere length. Carbohydrate was also negatively correlated with telomere length. Linolenic acid intake was positively 



























Table 45: Linear correlations for vitamin intake with plasma cytokine concentrations. Correlation analysis was performed on 
repeated measures of each variable, and age and sex were used as covariates. Additionally, all dietary intakes were adjusted for 















Table 46: Linear correlations for B vitamin intake with plasma cytokine concentrations. Correlation analysis was performed on 
repeated measures of each variable, and age and sex were used as covariates. Additionally, all dietary intakes were adjusted for 
total calorie intake. Vitamin B3 (niacin) intake was negatively correlated with IL-8 concentration. Vitamin B9 (folate) was 














Table 47: Linear correlations for mineral intake with plasma cytokine concentrations. Correlation analysis was performed on 
repeated measures of each variable, and age and sex were used as covariates. Additionally, all dietary intakes were adjusted for 















Table 48: Linear correlations for macronutrient, fatty acid, and fiber intake with plasma cytokine concentrations. Correlation 
analysis was performed on repeated measures of each variable, and age and sex were used as covariates. Additionally, all dietary 












3.10 Differences in study variables between cohorts 
 When comparing demographics, lipid levels, and cytokine concentration, the only 
significant differences found between study participants with a history of colorectal cancer and 
participants without a history of cancer were in participant’s age and in triglyceride level at day 
14. Individuals with a history of colorectal cancer were found to be significantly older than those 
without a history of cancer (µw-µw/o=20.9 years; 95% CI=[12.1, 29.7]; p=<0.0001). In regards to 
triglyceride level, individuals with a history of colorectal cancer were observed to have 
significantly greater levels of triglycerides compared to individuals without a history of 
colorectal cancer (RoGM=1.55; 95% CI=[1.06; 2.27]; p=0.024). This difference was not 
significant at day 0 (RoGM=1.42; 95% CI=[0.98, 2.07]; p=0.065) or at day 28 (RoGM=1.33; 
95% CI=[0.91, 1.93]; p=0.134). No significant differences were found in BMI, weight, total 
cholesterol, HDL, LDL, or any cytokine.   
 The only other significant differences between the two study cohorts were observed 
within nutrient intake. At day 0, individuals with a history of colorectal cancer were found to 
have significantly lower intakes of vitamin A (RoGM=0.51; 95% CI=[0.32. 0.81]; p=0.006), zinc 
(RoGM=0.73; 95% CI=[0.55, 0.98]; p=0.038), potassium (RoGM=0.72; 95% CI=[0.59, 0.87]; 
p=0.0017), and iron (RoGM=0.70; 95% CI=[0.50. 0.99]; p=0.041). These differences were not 
significant at day 14: vitamin A (RoGM=0.86; 95% CI=[0.59, 1.26]; p=0.4359), zinc 
(RoGM=1.14; 95% CI=[0.90, 1.44]; p=0.277), potassium (RoGM=1.02; 95% CI=[0.89, 1.17]; 
p=0.7349), and iron (RoGM=0.97; 95% CI=[0.78, 1.19]; p=0.740). At day 28, the difference in 
potassium intake between the two cohorts was switched, and individuals with a history of 
colorectal cancer were found to have significantly higher intake than the other cohort 




95% CI=[0.90, 1.55]; p=0.219), zinc (RoGM=1.18; 95% CI=[0.97, 1.44]; p=0.095), and iron 
(RoGM=1.01; 95% CI=[0.81, 1.26]; p=0.928) at day 28 were not significantly different between 
the two cohorts. 
Table 49: Comparison of age, weight, body mass index, total cholesterol, low-density lipoprotein, and high-density lipoprotein 
of study participants without a history of colorectal cancer (n=11) to participants with a history of colorectal cancer (n=29). 
Participants with a history of CRC were significantly older than participants without a history of CRC. Otherwise, no significant 
differences were observed between the two cohorts. All variables displayed above were normally distributed with similar 




Table 50: Comparison of serum triglyceride level of study participants without a history of colorectal cancer (n=11) to 
participants with a history of colorectal cancer (n=29). No significant difference was observed between the two cohorts. Serum 
triglycerides within the cohort of participants with a history CRC were not normally distributed, and a natural logarithm 
transformation of both cohorts was performed prior to analysis. A back transformation was performed on the difference of the 









Table 51: Comparison of plasma cytokine concentrations of study participants without a history of colorectal cancer (n=11) to 
participants with a history of colorectal cancer (n=29). Variables shown above include the substitution and extrapolation data set 
for the following cytokines: IL-2, IL-4, IL-6, IL-8, IL-10, and TNF. The quality controls of the VEGF immunoassay failed for the 
cohort of participants without a history of CRC, and therefore, VEGF was not compared between the two cohorts. No significant 
differences in cytokine concentrations were observed between the two cohorts. All cytokine data within both cohorts was not 
normally distributed, and a natural logarithm transformation was performed prior to analysis. A back transformation was 










Table 52: Comparison of sodium, calorie, protein, and total fat intake of study participants without a history of colorectal cancer 
(n=11) to participants with a history of colorectal cancer (n=29). No significant differences were observed between the two 






















Table 53: Comparison of dietary intake variables of study participants without a history of colorectal cancer (n=11) to 
participants with a history of colorectal cancer (n=29). Variables shown above include intake of vitamin A, vitamin C, zinc, 
calcium, potassium, iron, carbohydrate, saturated fat, and fiber. At day 0, vitamin A, zinc, potassium, and iron intake were 
significantly lower in participants with a history of CRC compared to those without a history of CRC. At day 28, potassium 
intake was found to be significantly higher in participants with a history of colorectal cancer. All displayed variables were not 
distributed normally, and a natural logarithm transformation was performed prior to analysis. A back transformation was 














3.11 Correlation between experimental methods for telomere length measurement 
 Due to variability within the control cell line used for inter-batch comparison of telomere 
lengths as measured by IQ-FISH, correlation analysis between telomere lengths as measured by 
IQ-FISH and qPCR was performed relative to each IQ-FISH batch. In regards to batch one of 
IQ-FISH, multiplex qPCR telomere length was positively but non-significantly linearly 
correlated (r=0.3253; p=0.3357). For batch two, multiplex qPCR telomere length was also 
positively but non-significantly linearly correlated (r=0.2607; p=0.3205). Finally, for batch three 
of IQ-FISH, multiplex qPCR telomere length was positively and significantly linearly correlated 
(r=0.4793; p=0.0455).  
Table 54: Linear correlations between multiplex qPCR telomere length and respective batches of IQ-FISH telomere length 
Telomere length as measured by multiplex qPCR was positively correlated with all three batches of IQ-FISH. However, the only 
significant correlation between the two experimental methods for telomere length was observed between multiplex qPCR 
telomere length and IQ-FISH batch 3. Adjusted repeated measures correlations over three time points using sex as a covariate 

















4.1  No positive effect on plasma cytokine concentrations or leukocyte telomere length 
after dietary supplementation with rice bran or navy beans  
The primary hypothesis of this study was that individuals who consumed a navy bean or 
rice bran supplemented diet for 28 days would display decreased concentrations of pro-
inflammatory cytokines, increased concentrations of anti-inflammatory cytokines, and slower 
rates of leukocyte telomere length degradation when compared to individuals consuming a 
control diet. Similarly, it was proposed that the navy bean and rice bran diet groups at day 28 
would have decreased levels of pro-inflammatory cytokines compared to baseline values. These 
notions were based on the known anti-inflammatory effects of high dietary fiber intake, as well 
as the high concentration of phenolic compounds and other bioactive phytochemicals in both rice 
bran and navy beans.  
 
4.1.1 Relative increase in TNF and VEGF concentrations within navy bean diet group 
Contrary to predictions, no significant positive effect was found in plasma cytokine 
concentrations or leukocyte telomere length after dietary supplementation with rice bran or navy 
beans. In contrast, a pro-inflammatory response was observed as individuals with a history of 
colorectal cancer who consumed a navy bean supplemented diet were found to have significantly 
higher plasma concentrations of TNF and VEGF at day 28 than individuals who consumed a 
placebo-control diet. As consumption of cooked navy beans has previously been shown to reduce 




concentrations within the navy bean treatment group compared to the control group is 
unexpected and difficult to interpret.[208]  
A potential cause of the pro-inflammatory effects observed with consumption of the navy 
bean diet is that the navy bean powder used in this study could have contained low levels of a 
mitogenic glycoprotein, phytohemagglutinin (PHA).[227] PHA is a lectin produced by legumes 
that is well known for its toxic effects.[227-239] Previous studies have found that the 
concentration of PHA in uncooked beans is very high and typically ranges from 1,000 to 10,000 
ppm.[240] However, as PHA is heat-labile, it is undetectable in properly cooked beans when 
measured using an ELISA method with a sensitivity of 30 ppm.[241-244] Given that the navy 
bean powder in this study was obtained from a commercial source and was cooked in accordance 
with industry standards, it is less likely any hypothetical existence of PHA was a result of beans 
being improperly prepared. Therefore, if PHA was present in the navy bean powder used in this 
study, it is most likely to have been in concentrations below 30 ppm, which would correspond to 
a maximum daily intake of 1.05 milligrams per day per participant. As previous in vitro 
experiments have found that TNF and VEGF secretion by leukocytes is stimulated by PHA 
treatment, it is possible that the increase in plasma TNF and VEGF concentrations observed in 
this study was a result of sustained, low dose PHA exposure.[245-248] However, currently, the 
explicit effects of chronic ingestion of low residual PHA are unknown, and accounts of PHA 
consumption by humans are related to acute ingestion of raw or under-cooked beans.[249-251] 
Consequently, further evaluation of potential PHA content within the cooked navy bean powder 
used as a dietary treatment in this study is indicated in order to clarify if it is a possible cause of 
the significant difference in plasma TNF and VEGF concentrations between the navy bean and 




4.1.2  Study limitations and potential factors influencing results 
While no other significant outcomes were observed in regards to plasma cytokine 
concentrations or rate of leukocyte telomere shortening after dietary supplementation, the 
reasons for this are likely due to other influences rather than the inefficacy of rice bran and navy 
beans. Possible explanations for not obtaining results in accordance with the study’s primary 
hypothesis include the short duration of the study, the relatively small sample size of the study, 
and the significant differences in cytokine concentrations and leukocyte telomere length between 
sexes. Other factors possibly involved include the chosen dosage of the rice bran and navy bean 
interventions and the cultivar of rice bran and navy beans used. Additionally, uncontrolled for 
inter-individual factors within the study population such as physical activity, psychosocial 
elements, socioeconomic status, and the use of immunomodulatory medications could 
conceivably have influenced the outcome of the study.   
 In comparison to other studies that have investigated the effects of dietary intervention on 
systemic cytokine concentrations, the duration of this study is relatively short, and as a result, the 
hypothesized effects of navy bean and rice bran supplementation may require a longer term of 
dietary intervention in order to be demonstrated. Prior high-fiber dietary intervention trials have 
shown significantly decreased plasma IL-6, TNF, and IL-8 concentrations within as short a 
period as 6 weeks, so it is possible that slightly prolonged intervention with rice bran or navy 
beans would have demonstrated favorable anti-inflammatory effects.[252] Nevertheless, the 
effects of dietary interventions are more consistently demonstrated with longer extents of 





  Similarly, due to the short duration of the study, it is reasonable that no significant 
changes in telomere length were observed. The majority of longitudinal studies of leukocyte 
telomere length typically only detect significant changes after several years instead of weeks, 
with only one known study observing a significant change in as little as six months.[256-260] In 
general, because most circulating mature leukocytes are myeloid-derived cells that are terminally 
differentiated and lack the capability to replicate, leukocyte telomere length is primarily a 
reflection of the telomere length of hematopoietic stem cells.[261, 262] While hematopoietic 
stem cells possess low levels of telomerase activity, these levels are insufficient to prevent 
incremental telomere loss with each cellular replication, which in healthy adults is estimated to 
occur at a rate ranging from 0.6 to 2.2 times per year.[261, 263-265] Given these estimates, 
within a time frame of four weeks, only between 4.6% and 16.9% of hematopoietic stems cells 
would be expected to have replicated, which realistically indicates that a change in average 
peripheral leukocyte telomere length would be relatively small. Therefore, in order to fully 
evaluate the potential impact of rice bran or navy bean dietary supplementation on the rate of 
telomere length attrition, a longer time of dietary intervention is required.  
If a sustained dietary intervention is not practical, another possible biomarker of interest 
for gauging the effect of short-term diet supplementation is the measurement of the activity of 
telomerase, the enzyme responsible for telomere elongation. One study interested in the effect of 
comprehensive lifestyle changes in men with a history of prostate cancer found significant 
increases in telomerase activity compared to a control group after only three months of 
intervention.[266] A subsequent follow up study of this population showed those with increased 
telomerase activity at three months had longer telomeres five years later.[256, 266] Therefore, at 




telomerase activity over weeks with follow up measurement of telomere length months to years 
later.  
 Another possible explanation for not observing a significant effect of rice bran or navy 
bean supplementation on inflammatory cytokine concentrations or telomere length is the study’s 
limited statistical power secondary to the small number of individuals within each cohort and 
diet group. This is an issue as a study with a low statistical power has a decreased likelihood of 
revealing a true effect. Therefore, it is possible that a repeated study with a large sample size 
could demonstrate the proposed systemic anti-inflammatory effects of navy bean and rice bran 
consumption. In this report, when using the variances associated with diet group cytokine 
concentration and telomere length data at day 28 from the cohort of individuals with a history of 
colorectal cancer, the estimated total sample size required to achieve an 80% chance of detecting 
a significant result (p<0.05) ranged from 51 to 615 depending on the respective variable used for 
calculation.[267] These estimates are noticeably larger than the sample sizes used in this study, 
where only a total of 34 participants had cytokine values measured and 27 participants had 
telomere length measured.  
 In addition to the small sample size, the presence of both males and females in this study 
is another possible confounding influence that may have prevented demonstration of the anti-
inflammatory effects of rice bran and navy bean diets on cytokine concentration and leukocyte 
telomere length. Specifically, significant differences between males and females in leukocyte 
telomere length and IL-2, IL-4, IL-6, IL-8, and IL-10 concentrations lead to segmentation of the 
already small sample size and thus, effectively further reduced the statistical power of the study.  
While a two-way ANOVA analysis interested in the effects of sex and diet group on 




and diet group, there were perceptible differences in results when analysis was performed with 
the consideration of potential gender influences. For example, consider the noticeable effect that 
including sex has in the comparison of average leukocyte telomere length between the navy bean 
and control diets at day 0 and day 28. In a model that does not account for the influence of sex, 
the navy bean group (n=10) was observed to have an average relative telomere length compared 
to the control group (n=10) that was 6.4% longer at day 0 (p=0.6150) and 11.7% longer at day 28 
(p=0.3450). In a two-way ANOVA model that accounted for the effect of sex, the navy bean 
group was estimated to have an average relative telomere length compared to the control group 
that was 30.4% longer at day 0 (p=0.108) and 36.7% longer at day 28 (p=0.060). While the 
interaction between the independent variables of diet and sex was non-significant, the marked 
difference in p-values at day 28 between the one-way and two-way ANOVA models does 
demonstrate how, in the setting of a small sample size, the variable of sex had an observable 
influence on study outcomes. In future studies with a substantially larger sample size, this effect 
would likely be minimized due to greater intra-gender variability within the sample population.  
 Another possible explanation for not confirming the study’s hypothesis is that the chosen 
levels of rice bran and navy bean supplementation may not have been sufficient. In this study, 
intervention diets were supplemented with either 35 grams per day of navy bean powder or 30 
grams per day of rice bran powder. These dosages are in alignment with the levels of dry bean or 
rice bran intake in other studies that have found significant associations with markers of positive 
health.[268, 269] Yet, overall, there is a lack of data on what amount of daily intake of rice bran 
or navy beans is necessary in order to observe their beneficial effects, and it is probable that a 
larger degree of supplementation would induce a greater effect on both cytokine concentrations 




Determining an effective and realistic degree of dietary supplementation is difficult. In 
regards to inflammatory cytokines, separate studies on mice have found that intake of 40 grams 
per kilogram of rice bran or 740 grams per kilogram of navy beans can each decrease plasma IL-
6 levels.[205-207] Obviously, in humans, these levels of intake are not practical and are most 
likely not necessary to achieve significant reductions in systemic inflammation. In regards to 
humans, dietary intervention studies interested in the effects of rice bran on cholesterol have 
shown that intakes of 100 grams per day, 84 grams per day, and 60 grams per day can be well 
tolerated and are also effective at controlling dyslipidemia.[270-272] Similarly, high levels of 
bean intake were well tolerated by participants within the Polyp Prevention Trial, which found 
individuals in the highest two quartiles of dry bean intake (30.6-233.0 grams per day) had 
significantly lower levels of serum IL-6 as well as a reduction in risk of advanced colorectal 
adenoma recurrence.[253, 268] Given that these studies indicate that larger consumption of rice 
bran and navy beans is clearly possible, and in light of a lack of data on the amount of 
supplementation that constitutes an effective treatment, it is worth considering during future 
dietary interventions to assess the relative differences between tiered quantities of rice bran or 
navy bean supplementation. Similarly, it would likely be valuable to evaluate the effects of a 
combination treatment of both navy beans and rice bran.   
The incredible diversity of both rice bran and navy bean varieties must also be considered 
when assessing the effect of these foods on inflammatory markers and telomere length. The 
sheer volume of rice and bean cultivars is evidenced in the over 130,000 varieties of Oryza spp. 
and over 16,000 varieties of Phaseolus vulgaris L. stored in bio-repositories worldwide.[273, 
274] This remarkable genetic diversity results in discernable differences in each variety’s 




investigated the effects of one variety of each food type (a non-pigmented brown rice bran and a 
white navy bean), the possibility exists that other varieties of rice bran or beans may be more 
potent inducers of anti-inflammatory responses. Therefore, further research on the relative 
effects of dietary intervention with a diverse selection of rice bran or beans is warranted.  
The influence of non-dietary lifestyle factors may also have had an influence on the 
results of this study. Unfortunately, this analysis did not control for elements that previous 
studies have indicated are associated with both plasma cytokine concentrations and leukocyte 
telomere length. In particular, physical inactivity [281-287], emotional stress [288, 289], 
depression [290-294], and low socioeconomic position [295-298] have each been separately 
correlated with both shorter telomere lengths and increased inflammatory markers. These studies 
suggest that the effects of dietary intervention with rice bran or navy beans cannot be fully 
elucidated without a full understanding of each individual’s physical, emotional, and social 
status.  
Another conceivable influence that was not evaluated in this study is the potential that 
participants may have taken immunomodulatory medications during the intervention trial. To 
this author’s knowledge, the only enrollment criteria in relation to medication usage were that a 
participant may not have taken oral antibiotics or anti-hyperlipidemia agents within a month 
prior to the start of the trial and also must have been at least four months removed from any 
chemotherapy or radiation treatment. Therefore, it is possible that participants may have used 
other medications with immunoregulatory potential, such as non-steroidal anti-inflammatory 
drugs, glucocorticoids, cytostatic agents, and anti-TNF agents.  
Given that there is moderate to strong evidence for NSAID use in the prevention of 




during the trial.[299-304] Currently, the effect of NSAIDs on systemic cytokine levels is not 
entirely understood and is likely dependent on the type, frequency, and amount of NSAID used. 
While a select number of studies have found that NSAID use, particularly aspirin use, is 
significantly associated with lower levels of IL-2, IL-6, and IL-10 and higher levels of TNF 
[305-308], a similar number of studies have found no observable associations between NSAIDs 
and plasma cytokine levels.[309-313] Additionally, prior studies have indicated that the effect of 
NSAID use on circulating cytokine levels can be synergistically or antagonistically altered by 
supplementation of dietary components, such as folic acid and omega-3 fatty acids.[314, 315] In 
relation to leukocyte telomere length, comprehensive studies on NSAID use are severely lacking. 
In the only known study, no significant association was found between leukocyte telomere length 
and the use of NSAIDs once per week in a population of 300 participants at risk for esophageal 
cancer.[316, 317] Overall, given the lack of conclusive evidence on NSAIDs’ effect on plasma 
cytokine concentrations and leukocyte telomere length, it is unclear if accounting for NSAID use 
would have meaningfully impacted the results of this study.  
Similar to NSAIDs, the potential use of immunomodulatory medications such as 
glucocorticoids, cytostatic agents, or anti-TNF agents was not evaluated in this analysis. 
Additionally, the etiology of participants’ colorectal cancer was not considered. Given that 1-2% 
of all colorectal cancers are associated with a coexisting diagnosis of inflammatory bowel 
disease (IBD), the possibility exists that participants in the study possessed a history of colitis-
associated colorectal cancer and therefore may have managed their IBD symptoms with routinely 
prescribed medications such as budesonide, methotrexate, or infliximab.[318-323] The potential 
use of steroids, cytostatic agents, and anti-TNF agents during the intervention trial is an issue 




plasma concentrations.[247, 323-332] Furthermore, cytostatic agents, which directly inhibit 
nucleic acid synthesis, have been associated with decreased telomerase activity in peripheral 
leukocytes and therefore may influence the rate of telomere length shortening in long-term 
users.[333, 334]    
 
4.2 Multiple individual dietary factors correlate with plasma cytokine level, leukocyte 
telomere length, and serum lipid concentrations 
 A secondary objective of this study was to investigate potential correlations between 
plasma cytokine concentrations, leukocyte telomere length, serum lipid profile, and nutrient 
intake. Based on prior research, it was hypothesized that poor dietary habits would be associated 
with dyslipidemia, increased inflammatory cytokines, and shorter leukocyte telomere length. 
Overall, the significant correlations found in the present study were consistent with this 
hypothesis. Additionally, the significant correlations found support recommendations for 
maintaining a healthy diet.   
 
4.2.1 Cytokine correlations 
 For plasma cytokine concentrations, after adjusting for the influences of age, sex, and 
total energy intake, only a few significant correlations were found: α-Tocopherol intake was 
inversely correlated with IL-2 and IL-4, vitamin B3 intake was inversely correlated with IL-8, 







4.2.1a IL-2 and IL-4 both inversely correlated with α-Tocopherol intake  
 The inverse association of α-Tocopherol intake with plasma levels of IL-2 and IL-4 is 
consistent with findings of multiple in vitro and animal studies.[335-342] However, there is a 
lack of human clinical trial or observational data on the association of α-Tocopherol intake and 
plasma IL-2 or IL-4 concentrations. Overall, the majority of published studies on α-Tocopherol 
intake and cytokine concentrations in humans have focused on cytokines other than IL-2 and IL-
4, and unlike the present study, these studies have found significant inverse associations between 
α-Tocopherol intake and pro-inflammatory cytokines IL-6, IL-8, and TNF.[343-346]  
α-Tocopherol is one of eight isoforms of vitamin E and is a fat-soluble antioxidant that 
potently prevents oxidation of phospholipid membranes and plasma lipoproteins.[347, 348] Lipid 
peroxidation caused by free radical driven chain reactions is attenuated by α-Tocopherol due to 
peroxyl radicals having a nearly 1,000 times greater affinity for α-Tocopherol than for fatty 
acids.[348] Additionally, beyond a general antioxidant role, α-Tocopherol directly modulates 
several signal transduction pathways through inhibition of various transcription factors, and high 
doses of α-Tocopherol are associated with the up-regulation of anti-inflammatory peroxisome 
proliferator-activated receptor gamma (PPAR-γ) expression and down-regulation of pro-
inflammatory NF-κΒ activity.[336, 349] As gene expression of both IL-2 and IL-4 is inhibited by 
PPAR-γ and promoted by NF-κB, α-Tocopherol is likely to influence plasma IL-2 and IL-4 
concentrations through these pathways.[336, 337, 350, 351]  
However, while α-Tocopherol has vigorous anti-inflammatory effects that have been 
demonstrated mechanistically, in vitro, and observationally, there is a lack of evidence for the 
ability of α-Tocopherol supplementation to reduce cancer risk.[352] A large dietary intervention 




no reduced risk of colorectal cancer in a population of over 25,000 male smokers.[353, 354] A 
similar study found no reduced risk of colorectal cancer after α-Tocopherol supplementation 
(400 IU per day) for over 5 years in a population of over 35,000 healthy males.[355] Therefore, 
while in the present study α-Tocopherol is correlated with reduced IL-2 and IL-4, the evidence 
for a strong chemoprevention effect of α-Tocopherol intake is currently lacking.  
 
4.2.1b IL-8 inversely correlated with vitamin B3 intake 
 In regards to other cytokine correlations, the inverse association between IL-8 and 
vitamin B3 intake is consistent with previous in vitro, animal, and human clinical trial 
experiments.[356-361] Dietary vitamin B3, also known as niacin, is a water-soluble vitamin that 
is a precursor for the coenzymes nicotinamide adenine dinucleotide (NAD
+
/NADH) and 
nicotinamide adenine dinucleotide phosphate (NADP
+
/NADPH).[362] These coenzymes not 
only play vital roles in energy metabolism as electron carriers in oxidation-reduction reactions, 
but also are implicated in biomolecule synthesis, gene expression, calcium homeostasis, 
oxidative stress reduction, and apoptosis.[363] Furthermore, low cellular NAD
+
 concentration 
activates a regulatory nuclear enzyme, poly(ADP-ribose) polymerase-1 (PARP-1), and PARP-1 
stimulation leads to the promotion of several pro-inflammatory transcription factors, including 
NF-κΒ.[364] Given IL-8 production is primarily produced and secreted by macrophages through 
NF-κΒ pathways, the inverse association between dietary vitamin B3 intake and plasma IL-8 




 The negative correlation with IL-8 concentration also indicates a conceivable protective 




colorectal cancer have found that IL-8 promotes tumor growth, metastasis, and angiogenesis, and 
several studies have identified IL-8 as a potential therapeutic target for colorectal cancer.[365, 
366] However, direct interventional evidence for the ability of vitamin B3 to decrease IL-8 
concentrations or colorectal cancer risk is lacking.[367] Therefore, while higher vitamin B3 
intake is associated with lower plasma IL-8 concentration, more research is required in order to 
fully evaluate the potential chemoprevention effects of vitamin B3. 
 
4.2.1c VEGF positively correlated with vitamin B9 intake 
 The final significant cytokine correlation found in this study was a positive association 
between vitamin B9 intake and plasma VEGF concentration. Vitamin B9, otherwise known as 
folate, is a water-soluble vitamin that is essential for multiple metabolic pathways through its 
function as a single-carbon donor in the de novo synthesis of thymidylates and purines and in the 
re-methylation of homocysteine to form methionine.[368] While all cell types require vitamin B9 
in order to survive, the relative necessity of each cell varies with metabolic activity, and in the 
majority of somatic cells, vitamin B9 requirements are comparatively low compared to the 
requirements of fast growing cells.[369] In order to satisfy metabolic demands, fast growing 
cells, such as those found in tumors, preferentially express the high-affinity vitamin B9 
transporter, Folate Receptor alpha (FR-α).[369] Binding with FR-α by vitamin B9 not only leads 
to cellular uptake, but also activates several growth-promoting transcription factors, including 
STAT3.[370] Therefore, given VEGF expression is directly regulated by STAT3, the significant 
positive association between folate intake and VEGF in the present study may conceivably be a 
result of FR-α activation in fast growing cells.[76] As correlation analysis only assessed 




levels of folate intake are triggering increased VEGF expression by activation of the FR-
α/STAT3 pathway in enduring malignant cell populations. However, further investigation is 
ultimately required to fully elucidate the mechanism behind the correlation between VEGF and 
vitamin B9. 
 The relationship of vitamin B9 intake and colorectal cancer risk is not entirely 
understood. In epidemiological studies, high vitamin B9 intake was initially indicated to lower 
colorectal cancer risk through presumably modulating mechanisms for DNA synthesis, repair, 
and integrity.[371-375] However, several meta-analyses of randomized clinical trials on vitamin 
B9 supplementation have found no association with colorectal cancer risk,[376-380] and there is 
some evidence that vitamin B9 supplementation can increase the risk of colorectal cancer and 
other cancers.[381-383] While the effects of intracellular vitamin B9 deficiency on actively 
dividing pre-neoplastic and neoplastic cells is well demonstrated by in vitro studies and is the 
basis for widely used anti-folate chemotherapeutics such as 5-fluorouracil, the impact of vitamin 
B9 intake in general populations is difficult to predict. It is likely that vitamin B9 inhibits tumor 
initiation in normal cells and promotes survival, proliferation, and angiogenesis in malignant 
cells.[384, 385]  
   
4.2.2 Telomere length correlations 
 In relation to leukocyte telomere length, after adjusting for age, sex, and total energy 
intake, telomere length was found to be significantly inversely associated with serum triglyceride 
level, carbohydrate intake, and saturated fat intake. Additionally, telomere length was found to 




prior studies.[258, 386, 387] No other variables were significantly correlated with leukocyte 
telomere length.  
 
4.2.2a  Telomere length inversely correlated with triglycerides 
 Triglycerides are comprised of three fatty acid chains that are bonded to a three-carbon 
carbohydrate backbone via an ester bond, and circulating serum triglyceride levels are primarily 
driven by carbohydrate intake.[388] Additionally, high saturated fat intake, particularly medium 
chain saturated fatty acid intake, is strongly correlated with increased serum triglycerides as well 
as increased free serum saturated fatty acids.[389-391] Elevated levels of serum triglycerides and 
free saturated fatty acids are associated with pro-inflammatory processes through NF-κΒ activity 
and reactive oxygen species generation, and this increased oxidative stress thus promotes 
increased rates of telomere shortening.[392-396] In accordance with these mechanisms, 
observational studies have previously demonstrated significant associations between higher 
serum triglyceride level, saturated fat intake, and carbohydrate intake with shorter leukocyte 
telomere length.[397-401]  
 
4.2.2b Telomere length inversely correlated with carbohydrate and saturated fat intake 
In regards to colorectal cancer, while both high triglyceride level and shorter telomere 
length have each been independently and consistently correlated with risk of colorectal cancer 
incidence and recurrence, studies investigating the relationship between total saturated fat or 
carbohydrate intake and risk of colorectal cancer incidence or recurrence have been inconsistent 
with the majority of studies having found no significant association.[144, 402-419] Therefore, 




the present study, further research is required in order to determine if decreasing saturated fat or 
carbohydrate intake promotes colorectal cancer prevention.  
 
4.2.3 Lipid profile correlations 
 Several dietary factors were found to be associated with serum lipids. Dietary 
components associated with positive influences on lipid parameters included β-Carotene, 
linolenic acid, and fiber. Conversely, saturated fat and selenium were associated with negative 
effects on lipid levels.   
 
4.2.3a Total cholesterol, LDL, and triglycerides inversely correlated with β-Carotene intake 
 β-Carotene is a fat-soluble, pigmented antioxidant that was negatively correlated with 
serum levels of total cholesterol, LDL, and triglycerides in the present study. While prior studies 
have found that β-Carotene intake is strongly associated with decreased markers of plasma lipid 
oxidation, associations between β-Carotene intake and circulating concentrations of lipoproteins 
and triglycerides have been inconsistent.[420-427] The majority of studies in humans have found 
β-Carotene intake is associated with either no significant change or only a small decrease in total 
cholesterol and triglycerides.[420, 422, 424, 425] However, strong evidence for an anti-
hyperlipidemic effect from β-Carotene intake was found in a recent study on rats where β-
Carotene supplementation was associated with reduced serum levels of total cholesterol and non-
HDL cholesterol and increased fecal total cholesterol content.[428] Given β-Carotene is a fat-
soluble vitamin that is absorbed in the small intestine with other lipophilic molecules, including 
cholesterol and triglycerides, it was proposed that β-Carotene supplementation may reduce total 




Ultimately, a similar mechanism may be responsible for the inverse correlation between β-
Carotene intake and lipids in the present study. However, further research is required in order to 
fully understand the mechanism behind the association.    
 
4.2.3b HDL positively correlated with linolenic acid intake; total cholesterol and HDL 
positively correlated with saturated fat intake 
 The observed correlation between increased lipid levels (total cholesterol and HDL) and 
high saturated fat intake is well known and is consistent with previous studies.[430, 431] Current 
dietary recommendations call for substitution of saturated fats with polyunsaturated fats in order 
to improve lipid profile.[430] Linolenic acid is a polyunsaturated fatty acid that was positively 
correlated with serum HDL levels in the present study, and linolenic acid is found in two 
isoforms: α-Linolenic acid and γ-Linolenic acid. α-Linolenic acid is an ω-3 fatty acid and γ-
Linolenic acid is an ω-6 fatty acid. In regards to previous studies, both ω-3 fatty acids and ω-6 
fatty acids have been associated with improved lipid status, and specifically, there is strong 
evidence to support ω-3 supplementation for increasing HDL cholesterol.[431-436] Therefore, in 
the context of prior studies and the significant correlations found in the present study, it is highly 
suggested to replace saturated fats with polyunsaturated fats in order to improve serum lipid 
profile and overall health.  
 
4.2.3c Triglycerides inversely correlated with fiber intake and positively correlated with 
selenium intake 
 Finally, triglyceride levels were negatively correlated with fiber intake and positively 




by a recent meta-analysis of randomized control studies found a non-significant, negative 
association between triglycerides and dietary fiber.[437] In regards to selenium intake, the 
observed correlation is supported by a large scale cross-sectional study of over 5,000 adults with 
non-deficient selenium levels that found those with higher serum selenium had elevated serum 
triglyceride levels.[438] Therefore, given these findings and the correlations in the present study, 
clinical management of hypertriglyceridemia may benefit through consideration of total fiber and 
selenium intake.  
 
4.2.4  Dietary patterns associated with healthy lifestyles 
 Recent studies indicate that dietary patterns characterized by predominately plant-based, 
minimally processed foods are most strongly associated with health promotion and disease 
prevention.[439] Given the strong influence of diet on health, the prevention of chronic disease 
requires the consideration of dietary patterns. In regards to the present study, the observed 
significant correlations support recommendations for dietary patterns designed to promote 
healthy living. Specifically, the correlations in this study indicate relatively higher intakes of 
antioxidants and fiber and lower intakes of carbohydrates and saturated fats are associated with 
improved markers of inflammation and aging. Therefore, it is important to consider these factors 
in maintaining health, and ideally, the sources of dietary components should be obtained from 







4.3 Correlation between qPCR and IQ-FISH methods for telomere length measurement 
is non-robust 
 A final objective of the study was to assess correlation between two different 
experimental methods for telomere length measurement, IQ-FISH and qPCR. Unfortunately, due 
to variation within the control cell line used for IQ-FISH, correlation between the two methods 
was only possible on a limited number of samples within each IQ-FISH batch. However, a 
significant positive correlation was found between IQ-FISH telomere lengths for batch 3 and the 
corresponding samples that were measured by multiplex qPCR.  
 
4.3.1 Variability in telomere length of controls as measured by IQ-FISH 
Inter-batch comparison of telomere length measured by IQ-FISH was complicated by the 
different effect that normalization to the Raji cell line produced relative to results obtained after 
normalization to the LY-S cell line. Normalization to the Raji cell line resulted in individuals in 
batch two having the relatively longest telomere length (2.21), followed by batch one (1.69) and 
then batch three (1.67). The average fluorescence intensity of the Raji cell line was highest in 
batch one and lowest in batch three. Normalization to the LY-S cell line produced results that 
indicated individuals in batch three had the relatively longest telomere length (2.03), followed by 
batch two (1.79) and then batch one (1.75). The average fluorescence intensity of the LY-S cell 
line was highest in batch one and lowest in batch three. Normalization of each experimental 
batch to the Raji or LY-S control produced different results, and this finding indicates 
inconsistency in the repeated measurements of either the Raji or LY-S cell lines. Given these 




individual batches only, and IQ-FISH telomere lengths of individuals in different batches were 
not directly compared.  
To evaluate the inconsistency demonstrated within the repeat telomere length 
measurements of the Raji and LY-S control cell lines, the same slides that were initially used for 
2-D image acquisition were re-photographed using a different microscope that allowed for 26 Z-
axis images in 0.2 µm segments. These images were then compressed into a 2-D composite 
image and telomere length was re-estimated on 50 cells that had not previously been imaged. A 
mean fluorescence of these cells was used to re-measure telomere length within the control cell 
lines in order to evaluate if the relative fluorescence of the controls between the three 
experimental batches was consistent with the trends seen in the 2-D photographs.  
Comparison of the 2-D and 3-D fluorescence intensities for the respective batches of the 
Raji and LY-S control lines showed that the LY-S cell line had a similar trend in both the 2-D 
and 3-D images whereas the Raji cell line had contradictory results in the 2-D and 3-D 
measurements. For the 3-D measurements, the average fluorescence of the LY-S cell line in 
batch one, batch two, and batch three were 99.40, 72.62, and 61.51, respectively; these results 
align with the 2-D images which identified batch one as the highest intensity, followed by batch 
two and then batch three. Additionally, the use of LY-S as a control for telomere length 
measurement is supported by other studies that have shown maintenance of telomere length 
within this cell line.[440]  
For the Raji cell line, 3-D measurements revealed average fluorescence intensities of 
165.65, 64.90, and 99.21 for batch one, batch two, and batch three, respectively; these findings 
contradict the 2-D images which showed batch three to have the lowest average intensity. A 




Raji cell line may be caused by it being a carrier of the Epstein-Barr virus (EBV), which has 
been shown to promote telomere dysfunction and genomic instability.[441] EBV infection is 
associated with several illnesses and diseases, including Burkitt’s lymphoma, Hodgkin’s 
lymphoma, and infectious mononucleosis.[442-445] The Raji cell line is derived from a EBV-
positive Burkitt's lymphoma, and in one study that utilized FISH on metaphase chromosomes, 
EBV-positive Burkitt's lymphoma cell lines, including Raji, were found to have an abnormal 
number of telomeres in 37.2% of samples.[441] Additionally, EBV-positive cells were observed 
to have significantly increased prevalence of dicentric chromosomes, fragments, and chromatid 
gaps compared to mitogen-induced B-lymphoblast cell lines.[441] Therefore, it is likely the 
inconsistency in interphase FISH fluorescence intensities of repeated measurements of the Raji 
cell line is a result of DNA damage associated with latent EBV infection and ultimately indicates 
that the Raji cell line is a poor control for repeat experiments of interphase FISH telomere length 
measurement. The telomere dysfunction effect of EBV is a likely contributor to the failure of the 
standard curves within the singleplex qPCR experiments.  
 
4.3.2 Significant but non-Robust correlation between IQ-FISH and qPCR methods for telomere 
length measurement 
 No other prior studies are known to have correlated the methods of IQ-FISH and qPCR 
for telomere length measurement. A previous study has compared telomere length measurement 
by flow-FISH and qPCR, and in that study, FISH and qPCR correlated significantly in healthy 
individuals (r=0.33; p<0.0001) but not in patients with bone marrow failure or idiopathic 
pulmonary fibrosis (r=0.1; p=0.08).[446] In the present study, correlation results are inconclusive 




while the majority of the participant telomere lengths did not significantly correlate between the 
two methods. These findings are severely limited by the issue of sample size due to inability to 
directly compare inter-batch IQ-FISH measurements. Ultimately, in order to fully evaluate the 
correlation between the two methods, repeated measurements with a larger sample size is 
required. However, the preliminary results in this study do suggest a modest but limited 
correlation between the two methods.  
 
4.3.3  Benefits and disadvantages for IQ-FISH and qPCR methods for telomere length 
measurement 
 The methods for telomere length measurement used in this study each have inherent 
benefits and disadvantages that should be considered when designing future experiments. The 
benefits of the qPCR method include its low cost and amenability for high through-put 
experimental designs. However, a major disadvantage of the qPCR method is a lack of ability to 
compare results from different studies. The current method estimates a relative telomere length 
that is not comparable to results from other studies. This makes telomere lengths estimated by 
qPCR less useful for meta-analyses or retrospective review papers. While a procedure for 
absolute telomere length measurement by qPCR has been published, it has not been widely used 
and many researchers have reported difficulty with optimizing the standard curve require for this 
method.[447, 448] 
 In regards to interphase FISH, the advantages for this method include its ability to 
measure telomere length by FISH on non-actively dividing cells. However, this characteristic can 




cells. Additionally, other disadvantages includes that the FISH method requires a good deal of 










 The data and analysis in this thesis were completed as an ancillary component of a pilot 
dietary intervention trial interested in elucidating anti-inflammatory and anti-carcinogenic 
properties of whole grains and legumes. While an explicit demonstration of the proposed anti-
inflammatory and anti-aging effects of rice bran and navy beans was not observed in the present 
study, the findings and considerations in this thesis are intended to provide a basis for designing 
and optimizing a more expansive and integrated dietary intervention program. Ultimately, more 
novel research remains to be completed and more previously published findings need to be 
replicated in order to fully clarify and validate the health promoting effects of rice bran and 
beans.  
Indeed, in relation to cancer prevention, increased consumption of whole grains and 
legumes is an attainable lifestyle modification that is very likely to improve incidence and 
survivorship rates. However, the effects of whole grain and legume consumption must be 
considered in the context of other lifestyle factors or else the beneficial impact of these foods 
will be marginalized. Therefore, a multifaceted approach for cancer prevention that incorporates 
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6. Descriptive Statistics for Study Participants without a History of Colorectal Cancer 
 
Table 55: Descriptive statistics by time point of age (years), weight (kg), body mass index (kg/m
2
), and serum lipids (mg/dL) for 



























Table 56: Descriptive statistics by time point of IL-2, IL-4, IL-6, IL-8, IL-10, and TNF for study participants without a history of 
colorectal cancer (n=11). All cytokine values measured in picograms per milliliter. Three different approaches (deletion, 











Table 57: Descriptive statistics by time point of dietary intake data for study participants (n=11) without a history of colorectal 

























7. Descriptive Statistics of Study Participants with a History of Colorectal Cancer 
 
Table 58: Descriptive statistics by time point of age (years), weight (kg), body mass index (kg/m
2
), and serum lipids (mg/dL) for 


























Table 59: Descriptive statistics by time point and dietary intervention treatment of age (years), weight (kg), body mass index 
(kg/m
2
), and serum lipids (mg/dL) for study participants with a history of colorectal cancer. P-values less than 0.05 are indicated 











Table 60:  Descriptive statistics by sex of age (years), weight (kg), BMI (kg/m
2
), total cholesterol (mg/dL), LDL (mg/dL), HDL 
(mg/dL), and triglycerides (mg/dL) for individuals with a history of colorectal cancer. Female (F) and male (M) values displayed 
































Table 61: Descriptive statistics by time point of IL-2, IL-4, IL-6, IL-8, IL-10, TNF, and VEGF for study participants with a 
history of colorectal cancer (n=23). All cytokine values measured in picograms per milliliter. Three different approaches 








Table 62: Descriptive statistics by time point and dietary intervention treatment of interleukin-2 and interleukin-4 for study 
participants with a history of colorectal cancer. All cytokine values measured in picograms per milliliter. Three different 
approaches (deletion, substitution, and extrapolation) were used for managing left-censored data. P-values less than 0.05 are 















Table 63: Descriptive statistics by time point and dietary intervention treatment of interleukin-6 and interleukin-8 for study 
participants with a history of colorectal cancer. All cytokine values measured in picograms per milliliter. Three different 
approaches (deletion, substitution, and extrapolation) were used for managing left-censored data. P-values less than 0.05 are 















Table 64: Descriptive statistics by time point and dietary intervention treatment of interleukin-10 and tumor necrosis factor for 
study participants with a history of colorectal cancer. All cytokine values measured in picograms per milliliter. Three different 
approaches (deletion, substitution, and extrapolation) were used for managing left-censored data. P-values less than 0.05 are 















Table 65: Descriptive statistics by time point and dietary intervention treatment of vascular endothelial growth factor for study 
participants with a history of colorectal cancer. All cytokine values measured in picograms per milliliter. Three different 
approaches (deletion, substitution, and extrapolation) were used for managing left-censored data. P-values less than 0.05 are 































Table 66: Descriptive statistics by time point and sex of IL-2, Il-4, IL-6, IL-10, TNF, and VEGF for study participants with a 
history of colorectal cancer. All cytokine values measured in picograms per milliliter. Three different approaches (deletion, 
substitution, and extrapolation) were used for managing left-censored data. Female (F) and male (M) values displayed in adjacent 






Table 67: Descriptive statistics by time point of telomere length measured by multiplex qPCR, interphase FISH, and singleplex 
qPCR for study participants with a history of colorectal cancer. All telomere length measurements listed are relative estimates 
and do not possess units. Additionally, due to variability in telomere length of control samples, individual batches of interphase 
FISH are unable to be directly compared and are therefore listed separately. Similarly, variability was observed within control 
samples for singleplex qPCR telomere length measurements. For singleplex qPCR telomere measurements, descriptive statistics 
are shown for each individual plate as well as for the pooled set of samples after normalization to a control. P-values less than 































Table 68: Descriptive statistics by time point and dietary treatment group of telomere length measured by multiplex qPCR, 
interphase FISH, and singleplex qPCR for study participants with a history of colorectal cancer. All telomere length 
measurements listed are relative estimates and do not possess units. Additionally, due to variability in telomere length of control 
samples, individual batches of interphase FISH are unable to be directly compared and are therefore listed separately. Similarly, 
variability was observed within control samples for singleplex qPCR telomere length measurements. For singleplex qPCR 
telomere measurements, descriptive statistics are shown for each individual plate as well as for the pooled set of samples after 









Table 69: Descriptive statistics by time point and sex of telomere length measured by multiplex qPCR, interphase FISH, and 
singleplex qPCR for study participants with a history of colorectal cancer. All telomere length measurements listed are relative 
estimates and do not possess units. Additionally, due to variability in telomere length of control samples, individual batches of 
interphase FISH are unable to be directly compared and are therefore listed separately. Similarly, variability was observed within 
control samples for singleplex qPCR telomere length measurements. For singleplex qPCR telomere measurements, descriptive 
statistics are shown for each individual plate as well as for the pooled set of samples after normalization to a control. Female (F) 






































Table 70:  Descriptive statistics by time point of vitamin A (µg), β-Carotene (µg), vitamin C (mg), vitamin D (µg), vitamin E 
(mg), α-Tocopherol (mg), vitamin B1 (mg), vitamin B2 (mg), vitamin B3 (mg), vitamin B6 (mg), vitamin B9 (µg), and vitamin 
























Table 71: Descriptive statistics by time point and diet group of vitamin A (µg), β-Carotene (µg), vitamin C (mg), vitamin D (µg), 
vitamin E (mg), and α-Tocopherol (mg) for study participants with a history of colorectal cancer. P-values less than 0.05 are 

















Table 72: Descriptive statistics by time point and diet group of vitamin B1 (mg), vitamin B2 (mg), vitamin B3 (mg), vitamin B6 
(mg), vitamin B9 (µg), and vitamin B12 (µg) for study participants with a history of colorectal cancer. P-values less than 0.05 are 
















Table 73: Descriptive statistics by time point and sex of vitamin A (µg), β-Carotene (µg), vitamin C (mg), vitamin D (µg), 
vitamin E (mg), α-Tocopherol (mg), vitamin B1 (mg), vitamin B2 (mg), vitamin B3 (mg), vitamin B6 (mg), vitamin B9 (µg), and 
vitamin B12 (µg) for study participants with a history of colorectal cancer. Female (F) and male (M) values displayed in adjacent 























Table 74: Descriptive statistics by time point of zinc, calcium, potassium, sodium, iron, magnesium, and selenium for study 
participants (n=29) with a history of colorectal cancer. All mineral intakes were measured in milligrams. P-values less than 0.05 

































Table 75: Descriptive statistics by time point and dietary treatment group of zinc, calcium, potassium, sodium, iron, magnesium, 
and selenium for study participants with a history of colorectal cancer. All mineral intakes were measured in milligrams. P-values 











Table 76: Descriptive statistics by time point and sex of zinc, calcium, potassium, sodium, iron, magnesium, and selenium for 
study participants with a history of colorectal cancer. All mineral intakes were measured in milligrams. Female (F) and male (M) 




Table 77: Descriptive statistics by time point of calorie, protein, carbohydrate, fat, saturated fat, oleic acid, linoleic acid, 
linolenic acid, oleic acid, and fiber intake for study participants (n=29) with a history of colorectal cancer. All macronutrient 










Table 78: Descriptive statistics by time point and dietary treatment group of calorie, protein, carbohydrate, fat, and saturated fat 
intake for study participants (n=29) with a history of colorectal cancer. All macronutrient intakes were measured in grams. P-
























Table 79: Descriptive statistics by time point and dietary treatment group of oleic acid, linoleic acid, linolenic acid, and fiber 
intake for study participants (n=29) with a history of colorectal cancer. All macronutrient intakes were measured in grams. P-


























Table 80: Descriptive statistics by time point and sex of calorie, protein, carbohydrate, fat, saturated fat, oleic acid, linoleic acid, 
linolenic acid, oleic acid, and fiber intake for study participants (n=29) with a history of colorectal cancer. All macronutrient 
intakes were measured in grams. Female (F) and male (M) values displayed in adjacent columns. P-values less than 0.05 are 
indicated with a double-underline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
